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ABSTRACT
Klebsiella pneumoniae and Escherichia coli are two of the most clinically important 
pathogens of the family Enterobacteriaceae. Both can cause severe infections includ-
ing urinary tract infections (UTI), bloodstream infections (BSI) and pneumonia. 
Both are also involved in dissemination of antibiotic resistance. The prevalence of 
extended-spectrum β-lactamase- (ESBL) producing Enterobacteriaceae (EPE) and 
carbapenemase-producing Enterobacteriaceae (CPE) are increasing worldwide. 
This is a severe threat to public health, as antibiotic treatment becomes limited. The 
general aim of the thesis was to investigate the clonal diversity and prevalence of 
ESBL in invasive isolates of Klebsiella pneumoniae from the Stockholm area, the 
acquisition of EPE/CPE in healthy Swedish tourists travelling to regions with high 
prevalence of EPE/CPE, and finally to evaluate rapid detection and characteriza-
tion methods for EPE and CPE. 
In Paper I, we studied the clonal structure of K. pneumoniae from BSI patients in a 
well-defined geographical area, as well as the prevalence of ESBL in these strains. 
We also characterized the clinical isolates to investigate the association between 
phylogroups, bacterial virulence factors, 30-day mortality and comorbidity. A total 
of 139 samples were collected from the Department of clinical microbiology at 
Karolinska University Hospital, Stockholm, Sweden. Only five out of 139 isolates 
were detected as multidrug-resistant (MDR) and all five isolates were EPE. Only 
one isolate was detected as a CPE. Further, all isolates were tested for mucoid 
pheno types, serotypes (K1, K2, K5, K20, K54 and K57) and screened for virulence 
genes using real-time PCR. To identify risk factors, we retrieved data from medical 
records including age, sex, time to adequate treatment, hospital acquired infections, 
comorbidity and mortality. The 30-day mortality was primary end-point. All isolates 
were further subjected to multilocus sequence typing (MLST) for phylogenetic 
analysis. We found that all isolates were divided into three  distinct phylogroups; KpI 
(consisting of 96 isolates of K. pneumoniae) followed by phylogroup KpIII (consist-
ing of 34 isolates of K. variicola) and phylogroup KpII (consisting of 9 isolates of 
K. quasipneumoniae). We observed 24/139 (17.3%) overall 30-day mortality. We 
also observed that K. variicola KpIII (29.4%) were highly associated with 30-day 
mortality compared to K. pneumoniae KpI isolates (13.5%). We also observed that 
several comorbidities; malignancy, diabetes mellitus, cirrhosis, biliary tract disor-
ders and alcoholism among patients may influence the mortality. 
In Paper II, we evaluated a commercial version of RAPIDEC® CARBA NP for 
rapid detection of carbapenemases against 276 Gram-negative bacilli. According to 
the manufacturer’s protocol RAPIDEC® CARBA NP assay was performed on 138 
carbapenemase-producers and 138 non-carbapenemase-producers. Carbapenemase 
detection was also performed by using conventional and real-time PCR. A total 
of 135 out of 138 carbapenemase-producers were detected successfully by the 
RAPIDEC® CARBA NP assay. The RAPIDEC® CARBA NP assay was unable to 
detect one OXA-48-producing K. pneumoniae and two Acinetobacter  baumannii 
producing OXA-23 and OXA-24 carbapenemases. The RAPIDEC® CARBA NP 
assay successfully detected 135 non-carbapenemase producers. A total of two false 
positives; one Pseudomonas aeruginosa with OprD loss and efflux, one Enterobacter 
cloacae with impermeability were detected by the RAPIDEC® CARBA NP assay. 
The overall sensitivity and specificity of the RAPIDEC® CARBA NP assay was 
97.8% and 98.5%, respectively. 
In Paper III, we investigated the acquisition of EPE and CPE among healthy Swedish 
travellers visiting regions with high prevalence of EPE and CPE; Southeast Asia, 
Indian subcontinent, North Africa and the Middle East. We studied 188 healthy adult 
travellers and excluded 13 pre-travel colonized tourists from the analysis. Molecular 
characterization was performed using real-time PCR and survey data were collected 
for analysis. We detected a total of 67/175 tourist were colonized by EPE strains and 
most dominant species was E. coli (n=65), followed by K. pneumoniae (n=1) and 
Citrobacter freundii (n=1). CTX-M type (CTX-M-1 n=49, CTX-M-9 n=12) was the 
most prevalent EPE type detected in 61 isolates but carbapenemases were absent. 
Only six travellers had strains with the virulence factor pyelonephritis-associated 
pili-encoding genes (pap) genes, and all of those had travelled to India. One traveller 
to Thailand was colonized with colistin resistance gene mcr-1. The highest coloni-
zation rate was detected among the travellers to the Indian subcontinent (49%) and 
northern Africa (44%) whereas lower rates were detected in travellers to Southeast 
Asia (19%) and Turkey (10%). EPE colonization was associated with diarrhea and 
antibiotic treatment during the trip but was not associated with sex, age, duration 
of trip, intake of proton-pump inhibitors, or use of oral cholera vaccine. 
In paper IV, we assessed a CRISPR/Cas assisted optical DNA mapping method for 
rapid identification and characterization of plasmids during an EPE outbreak. We 
studied a total of 17 neonates initially colonized with ESBL-producing K. pneumoniae 
(ESBL-KP). In follow-up samples we observed that some of them were colonized 
with ESBL-producing E. coli. This method successfully detected two plasmids of 
different sizes; small size (80 kbp) and larger plasmid (162-222 kbp) in all ESBL-KP 
isolates. Using this method, we also observed that the blaCTX-M-15 gene was located on 
the smaller size plasmid. In follow-up samples we also observed that the ESBL-KP 
clone was present and blaCTX-M-15 was stable up to two years. This method demon-
strated that plasmids can change over time: three deletions were observed in three 
plasmids of three isolates with different sizes (~ 5 kbp), (~ 55 kbp) and (~ 31 kbp) 
and an inversion of 31 kbp in another isolate. This method also confirmed that 
resistance plasmids were not transferred from one patient to another. 
In conclusion, this thesis provides new knowledge on the prevalence of EPE and 
CPE among BSI patients and healthy Swedish tourists, along with describing the 
molecular features of ESBL- and carbapenemase-producing Enterobacteriaceae. 
This thesis also demonstrates the performance of a rapid phenotypic carbapenemase 
detection assay, as well as a novel CRISPR/Cas-assisted optical DNA mapping 
method for rapid plasmid characterization. 
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11 INTRODUCTION
1.1 Antibiotic resistance
In 1928, Sir Alexander Fleming serendipitously discovered a new drug with remark-
able properties; penicillin. Subsequently, related compounds were developed with 
even broader antimicrobial spectrum – the cephalosporins, the carbapenems, and 
the monobactams. The Greek words anti- (means against) and bios (means life) 
are the source of the word antibiotic. Antibiotics are the substances that can kill 
or inhibit the growth of bacteria. Antibiotics can be chemical agents such as sulfa 
compounds or can be derived from natural origin with a chemical modification 
such as Penicillium notatum. 
Micro-organisms capable of evading antibiotic action, commonly known as anti-
biotic resistance, is according to the World Health Organization (WHO) one of the 
greatest threats to human health. Estimates suggest that due to multidrug-resistant 
bacterial infections around 25,000 people are dying each year and the cost of treat-
ment is about €1.5 billion annually in EU countries (1, 2). Over 2 million people 
are infected annually with antibiotic-resistant bacteria in the United States and 
23,000 people are dying due to resistant bacterial infections (3) (4). It has been 
estimated that ten million people would die annually in 2050 if the development 
of resistance continues as now (5) (Figure 1). 
Figure 1.	Annual	estimated	deaths	due	to	antimicrobial	resistance	by	2050.	Rights	to	
reprint from amr-review.org5.
21.2  Mechanisms of antibiotic resistance 
Bacteria exhibit antibiotic resistance intrinsically or they can acquire it. Resistance 
mechanisms to some common antibiotics are listed in (Table 1) (6). Intrinsic 
resistance is the ability of a bacterium to resist antibiotic action by its inherent 
structural or functional characteristics. In comparison to Gram-positive bacteria, 
intrinsic resistance to a variety of compunds is rather common in Gram-negative 
due to i) differences in the composition of the cytoplasmic membrane; presence 
of anionic phospholipids is low in the cytoplasm of Gram-negative bacteria, 
ii) absence of susceptible targets and iii) inability of the antibiotics to cross outer 
membrane of Gram-negative bacteria. For example, vancomycin is active against 
Gram-positive bacteria by inhibiting peptidoglycan crosslinking by binding to 
D-Ala-D-Ala peptides, but it is not active against Gram-negative bacteria as it 
cannot reach to peptides in periplasm (7). 
Gram-negative pathogens can also acquire resistance through gene mutations or 
horizontal gene transfer. The mechanisms of acquired resistance can be classified 
in four main classes; (i) antibiotic modification/inactivation, (ii) antibiotic  target 
alteration, (iii) increased antibiotic efflux, and (iv) reduced antibiotic uptake 
(Figure 2) (8).  
Antibiotic inactivation can occur by hydrolysis of β-lactam antibiotics. The four-
membered β-lactam ring is hydrolyzed by β-lactamase enzymes (Figure 2A). Different 
groups of β-lactamases have been reported, which can inactivate different groups 
of antibiotics including, penicillin, cephalosporins and carbapenems (9). Some 
enzymes such as aminoglycoside N-acetyltransferases (AACs), amino glycoside 
O-nucleotidetransferases (ANTs) and aminoglycoside O-phosphotransferases (APHs) 
can modify aminoglycoside antibiotics to exhibit resistance against aminoglycoside 
antibiotics (10). 
Target alteration is another common mechanism of resistance against several classes 
of antibiotics where the target of antibiotic is changed. One example of such target 
alteration is DNA-topoisomerase complex. Mutation of the DNA gyrase encoding 
gene (gyrA) can alter the protein structure which reduces fluoroquinolone-binding 
affinity leading to resistance (11). Modification of specific nucleotides in the 
aminoglycoside binding site of 16S rRNA by 16S rRNA methylases can confer 
high-level aminoglycoside resistance (12). 
Bacteria use efflux pumps to force out antibiotics from the cell so that they can 
lower the antibiotic concentration to sublethal levels (Figure 2B). This is a first line 
defence and it can force out different compounds, depending on the specificity of 
the efflux pump. Using efflux pumps, bacteria can develop multidrug resistance, 
as they can simultaneously export drugs of different drug classes (13). 
3Table 1. Mechanisms of resistance to different classes of antibiotics against Gram-negative 
bacteria. Modified from Kumar et al 2013 with permission from the publishers6.
Antimicrobial 
class
Mechanism of 
Resistance
Specific means to achieve 
resistance
Examples
b-lactams Degradation of 
antibiotics
Destruction of b-lactam ring 
by b-lactamases making it 
incapable to bind to penicillin 
binding protein (PBPs)
Resistance to  penicillins, 
cephalosporins and 
carbapenems
Decreased uptake Decreased porin  channel 
formation
Carbapenem  resistance 
in K. pneumoniae, 
Enterobacter spp. and 
P. aeruginosa
Polymyxins Altered target Mutational changes in LPS. 
Modification of lipid A by 
enzyme MCR
Colistin resistance in 
K. pneumoniae and 
E. coli
Glycylcyclines Efflux Pump tigecycline and 
 eravacycline out of the cell
Tigecycline resistance 
in K. pneumoniae
Trimethoprim-
Sulfamethoxazole
DNA synthesis Acquisition of dfr and sul 
genes that can circum-
vent the  inhibitory effect of 
trimethoprim and sulfa in 
the synthesis pathway of 
tetrahydrofolate
Trimethoprim and 
 sulfonamide  resistance 
in E. coli and 
K. pneumoniae 
Permeability barrier 
and/or efflux
Permeability barrier and/or 
efflux act against both sul-
fonamides and trimethoprim
Trimethoprim and 
 sulfonamide  resistance 
in E. coli and 
K. pneumoniae
Aminoglycoside Enzymatic 
modification
AACs, ANTs and 
APH enzymes modify 
aminoglycoside 
Aminoglycoside resist-
ance in Gram-negative 
bacilli
Efflux Downregulation or  alteration 
of porin channels
Aminoglycoside resist-
ance in Gram-negative 
bacilli
Altered target Modification of ribosomal 
proteins or 16S rRNA
16S ribosomal RNA 
(rRNA) methylases in 
Enterobacteriaceae 
and P. aeruginosa and 
Acinetobacter spp.
Fluoroquinolones Decreased uptake 
and increased 
excretion
Alteration in the outer mem-
brane  diminishes uptake 
of drug. Activation of efflux 
pumps to excrete the drug
Fluoroquinolone resistant 
Gram-negative bacteria 
Altered target
Enzymatic 
modification
Changes in DNA gyrase 
and topoisomerase or target 
protection (Qnr)
AAC6´Ib-CR can confer FQ 
resistance through enzymatic 
modification
Fluoroquinolone resistant 
Gram-negative bacilli
Fluoroquinolone resistant 
Gram-negative bacilli
4Figure 2.	Different	mechanisms	of	antibiotic	resistance	(Rights	to	reprint	from	Essays	in	
Biochemistry8). 
Gram-negative bacteria can reduce uptake of antibiotics by altering outer mem-
brane permeability (Figure 2C). The outer membrane of Gram-negative bacteria 
is a barrier, but porins in the outer membrane facilitate the diffusion of small 
hydrophilic antibiotics such as β-lactam antibiotics. Gram-negative bacteria can 
acquire resistance through (i) down-regulation the expression of porins by mutations 
(e.g. loss of OmpF in Escherichia coli exhibits resistance to β-lactam antibiotics), 
(ii) substitution of smaller channel size porin with a large channel size porin (e.g. 
5Klebsiella. pneumoniae isolates exhibit resistance against β-lactam antibiotics by 
substitution of OmpK35 with a smaller channel size OmpK36), (iii) impaired porin 
function by mutation (e.g. permeation of benzylpenicillin is reduced in PenB porin 
of Neisseria gonorrhoeae by addition of two negatively charged amino acids in 
the channel-constricting loop 3) (14-16).  
1.3 Enterobacteriaceae 
Enterobacteriaceae is a family of rod-shaped Gram-negative bacteria, which are 
commensal inhabitants of the intestinal microbiota, but which are also a common 
source of both nosocomial and community-acquired infections. Enterobacteriaceae 
can cause a wide range of infections; cystitis, pyelonephritis, septicemia,  pneumonia, 
peritonitis, meningitis, and device-associated infections. K. pneumoniae and E. coli 
are the most common human pathogens within the Enterobacteriaceae family.
1.3.1 Klebsiella pneumoniae 
In 1882, Carl Friedlander first isolated Klebsiella pneumoniae from the lungs of 
a patient with pneumonia (17). Klebsiella species are abundant in nature, they 
can be found in plants, animals and humans. They are one of the most important 
member of family Enterobacteriaceae of Gram-negative pathogenic bacteria. They 
are non-sporulating, lactose-fermenting, facultatively anaerobic, rod-shaped and 
non-motile bacteria. They can cause severe infections in humans, including respira-
tory tract infections, urinary tract infections, and bloodstream infections (18). They 
can cause both nosocomial and community-acquired infections. Klebsiella species 
are the third leading cause of hospital-acquired infections in United States (19) 
and they are among the leading causes of ventilator-associated pneumonia among 
intensive care units’ patients (20). They are also considered as the second leading 
cause of bloodstream infections (BSI) among Gram-negative bacteria (18, 19).  
Capsule, lipopolysaccharides (LPS), fimbriae, siderophores (enterobactin, aero-
bactin, salmochelin, yersiniabactin) and efflux pumps are considered as the main 
virulence factors of K. pneumoniae (18). Furthermore, some virulence factors; 
fimbriae, capsule and enterobactins are ubiquitous in all isolates of K. pneumoniae 
(21). Hypervirulent K. pneumoniae (HvKP) isolates are associated with a  number 
of putative virulence factors; aerobactin and rmpA (regulator of the mucoid pheno-
type) both encoded by large virulence plasmids are present in hypervirulent HvKP 
isolates (22). Integrative and conjugative elements encoded iron acquisition sys-
tem, such as yersiniabactin, and allantoin metabolism associated regions can also 
be present in HvKP isolates (23, 24). Capsules are composed of polysaccharide 
forming thick bundle of fibrillous structures that covers bacterium to protect from 
macrophage-mediated phagocytosis and bactericidal serum factors (25). There 
are 78 different capsular (K antigen) types, most importantly K1, K2, K5, K20, 
K54 and K57 are highly associated with invasive disease of K. pneumoniae (26). 
61.3.2 Escherichia coli
Escherichia coli are non-sporulating, motile, lactose-fermenting, rod-shaped bac-
teria. They are also important member of the family Enterobacteriaceae of Gram-
negative bacteria. They are found in the normal microbiota of the digestive tracts 
of humans and animals. E. coli have 171 somatic (O), 55 flagellar (H) and 80 
capsular (K) antigens. Until today, there are over 160 serological types of E. coli. 
All these types are involved in causing different infections in human including, 
urinary tract infections (UTI), hospital-acquired pneumonia (HAP), sepsis, surgical 
site infection (SSI), gastrointestinal tract infections, hemolytic-uremic syndrome 
(HUS), meningitis and inflammation of the meninges, bloodstream infections 
(BSI), abdominal infections and pneumonia (27). Most E. coli are members of the 
commensal microbiota with low pathogenicity. In the mucus layer of the colon, 
E. coli are the most frequent facultative anaerobes with a quantity of 107-109 cfu/
gram of feces (28). 
Phylogenetic analysis of E. coli discloses eight phylogroups; A, B1, B2, C, D, E, 
F and clade I. Strains of the different phylogroups behave differently. Strains of A 
and B are mainly commensal bacteria, whereas strains of B and D are more virulent 
and pathogenic bacteria mostly associated with causing extra-intestinal infections 
(ExPEC) (29, 30). Virulence factors are important for a pathogen to attach with 
the mucosal surface of the host and to overcome immunologic response. The main 
virulence factors of uropathogenic E. coli include adhesins (e.g. pili associated 
with pyelonephritis (pap) encoding P-fimbriae and type 1 fimbriae encoded by 
fimH), toxins (e.g. alpha-hemolysin, cytotoxic necrotizing factor 1, autotransporter 
toxins), iron/heme acquisition systems and iron ion transporter, capsule produc-
tion (K1/K2/K5) (31).  
1.4 Antimicrobial resistance in Enterobacteriaceae 
Infections caused by Enterobacteriaceae are usually treated with β-lactam anti-
biotics. These are broad spectrum antibiotics consisting of molecular ring-shaped 
structure, the β-lactam ring (Figure 2A). This group include penicillins, cephalo-
sporins, monobactams and carbapenems. 
Hydrolysis of β-lactam structure mediated by β-lactamases is the most common 
resistant mechanism for inactivation of β-lactam antibiotics. There are mainly 
four β-lactamases groups which can be identified based on substrate specificities: 
penicillinases, AmpC-type cephalosporinases, extended-spectrum β-lactamases 
(ESBLs), and carbapenemases (32). Decreased porin function or increased efflux 
are other types of β-lactam resistance mechanism exhibited by Enterobacteriaceae. 
Porin alterations and β-lactamase production can synergize in increasing antibiotic 
resistance in many pathogens of Enterobacteriaceae (7). 
71.4.1 ESBL-producing Enterobacteriaceae (EPE)
Extended spectrum β-lactamases (ESBLs) are enzymes produced by 
Enterobacteriaceae that can hydrolyze β-lactam antibiotics mostly penicillins and 
cephalosporins but are susceptible to cephamycins and carbapenems (33). ESBLs 
were first described in Germany in 1983 (34), later a huge number of ESBLs have 
been detected. Several classification schemes are available, but the classification 
proposed by Giske et al in 2009 is most frequently used in Sweden and Norway 
(35). According to Giske et al classification, ESBL enzymes can be classified into 
three main groups; ESBLA, ESBLM and ESBLCARBA discussed in Table 2. 
Table 2. ESBL classification according to Giske et al classification35.
ESBLA, ESBLM ESBLCARBA
CTX-M, SHV and TEM AmpC, CMY and FOX KPC, NDM, VIM and OXA-48
Degraded by clavulanic acid Inhibited by cloxacillin KPC is inhibited by boronic acid
NDM and VIM are inhibited by 
DPA and EDTA 
OXA-48 is inhibited by 
avibactam
After the first discovery of CTX-Ms in the 1980s they have emerged in all con-
tinents. The blaCTX-M enzymes can be divided into five phylogroups; CTX-M-1, 
CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25. The worldwide most dominant 
CTX-M-15 belongs to phylogroup CTX-M-1 (36-38). 
The most well-known classification of β-lactamases is based on functional and 
molecular structure, Bush et al. classified β-lactamases into four groups in the 1995, 
“Group 1 cephalosporinases are not well inhibited by clavulanic acid, group 2 
(molecular class A or D) β-lactamases are commonly inhibited by active site-directed 
β-lactamase inhibitors, group 3 metallo-β-lactamases are poorly inhibited by all 
classical β-lactamase inhibitors excluding EDTA and p-chloromercuribenzoate 
(pCMB) and group 4 penicillinases that are not inhibited by clavulanic acid” (33). 
There is a homogenous distribution of ESBL genotypes observed in Nordic 
 countries. In Sweden, blaCTX-M-15 is found in 50-60% and blaCTX-M-14 found in 10-15% 
of ESBL-producing E. coli. In Norway and Denmark, blaCTX-M-15 and blaCTX-M-14 
were found in 50% and 20% respectively (39, 40). In Finland, CTX-M-1 including 
blaCTX-M-15 is the most prevalent ESBL genotype. Whereas, other parts of Europe 
have different ESBLs genotypes. In Spain, most prevalent ESBLs genotypes are 
blaCTX-M-14 and blaCTX-M-9 whereas blaCTX-M-3 is the most prevalent ESBL genotype in 
Poland as well as other eastern European countries (41, 42). Again, the blaCTX-M-15 
is the most prevalent genotype in the African and Australian continents and also in 
8Canada. In US the most prevalent ESBL genotype used to be blaSHV about a dec-
ade ago, but now blaCTX-M-15 has become the most prevalent ESBL type also there 
(43-45). Heterogenous distribution of genotypes is observed in Asian continent. In 
Japan, CTX-M-9 is the most frequently encountered phylogroup whereas in China 
it is CTX-M-14 and in India CTX-M-15. CTX-M-8 is rare in other continents but 
it is common in South America along with CTX-M-2 (43, 46-49).   
Transmission of EPE 
ESBL can disseminate either by emerging bacterial clones or by horizontal gene 
transfer. Multiple factors are involved in dissemination of EPE; including humans, 
animals and environmental factors. Several studies have reported the transmis-
sion between household contacts (50, 51). Dissemination within households was 
observed in 32% (9/28) during a Norwegian outbreak of infants colonized by EPE 
at the neonatal intensive care unit (52). EPEs has been found in pets, poultry,  cattle 
and birds (53-56). Dissemination of EPE in the community is very common in 
countries having high prevalence of intestinal EPE-colonization. Several other 
reservoirs for EPE are present, for example sewage water and the surface of fruits 
and vegetables (57, 58). NDM-1, ESBL and carbapenemase gene were reported 
from drinking water in New Delhi (59).  
Prevalence of asymptomatic EPE carriage is not uniform throughout the world. In 
Sweden, during 2012-2013 the prevalence was 4.7% whereas it was much higher 
in Thailand 65.7% (60, 61). During 2015 EPE carriage was 19% in a tribal area 
in India but it was much higher 58.4% in outpatients, which has been reported 
by a study of rectal swabs in pediatric oncology unit (62, 63). With considerable 
variation, nearly 50% of the Enterobacteriaceae clinical isolates were reported to 
show resistance against extended-spectrum cephalosporins in all WHO region by 
2014 (64). 
In this era of globalization, drug resistant bacteria are spreading rapidly all over 
the world. EPE colonization is highly associated with international travel and the 
risk is higher while travelling to prevalent area. The risk of acquisition of EPE is 
higher while travelling to southeast Asia, especially India. Diarrhea and use of anti-
biotics during travel are both independent risk factors for acquiring EPE (65-69). 
1.4.2 Carbapenemase-producing Enterobacteriaceae (CPE)
Carbapenemase production was detected in Enterobacteriaceae for the first time 
in 1993, in a clinical isolate of Enterobacter cloacae, in the form of a chromo-
somally encoded NmcA (70). Later, a wide variety of carbapenemases have 
been detected. Carbapenemases can be defined as the group of enzymes that can 
hydrolyze penicillins, in most cases cephalosporins and to varying degrees car-
bapenems and monobactams. The most clinically significant carbapenemases are; 
9Ambler class A, also known as functional group 2f, class B also known as group 
3 and class D also known as group 2d. Class A carbapenemases are based on the 
presence of serine residues in the active site. Enzymes of this class can hydrolyze 
penicillins, cephalosporins, carbapenems and the monobactam aztreonam, with 
exception of Guiana extended spectrum (GES) which cannot hydrolyze aztreonam. 
Clavulanic acid, tazobactam and boronic acid can inhibit most of the members 
of this group. KPC, GES and IMI are the examples of class A carbapenemases. 
Class B carbapenemases also known as metallo-β-lactamases (MBL) are a group 
of carbapenemases who require a zinc ion in the active site for hydrolysis of 
β-lactams. Ethylenediaminetetraacetic acid (EDTA) can inhibit the activity of 
this group of enzymes by chelation. MBLs are not inhibited by clavulanic acid or 
tazobactam. Verona integron-encoded (VIM), German imipenemase (GIM), Seoul 
imipenemase (SIM) are the examples of this group. Class D carbapenemases are 
one of the most predominant and diverse group of carbapenemases and have weak 
hydrolytic activity against carbapenems. Currently, there is a lack of available 
specific inhibitors for OXA-48 like enzymes; OXA-23, OXA-24 and OXA-58 
group. OXA-48 carbapenemases are identified in Enterobacteriaceae but OXA-48 
like genes were identified only in Acinetobacter baumannii worldwide (71, 72)
Worldwide dissemination of CPE
Dissemination of carbapenemase-producing Enterobacteriaceae is still rare in 
Sweden but it is increasing rapidly. In total 115 CPE were identified in Sweden 
in 2015, among them 43 were identified in Stockholm. Most of the isolates were 
identified from fecal screening samples. In 2007-2012, out of the total of 94 iso-
lates identified, 24 originated from clinical infections in Sweden (73). The Public 
Health Agency of Sweden reported a total of 144 cases of CPE in 2018 which is 28 
cases more than in 2017 (74). In the United States in 1996, KPC enzymes were first 
detected from a K. pneumoniae isolate showing resistance to all β-lactams. Epidemic 
outbreaks of CPE were reported from Greece, the USA and Israel in the early 2000. 
Now, KPC is the most prevalent carbapenemase among Enterobacteriaceae in 
Europe and it has spread in South America and China also. KPC is also regarded 
as endemic in Greece (75, 76). European Antimicrobial Resistance Surveillance 
Network (EARS-Net) data reported that in Slovakia, Greece and Italy, proportion 
of carbapenem resistant K. pneumoniae were observed 63%, 57% and 44% respec-
tively (77). KPC has been found both in Enterobacteriaceae and Pseudomonas 
aeruginosa, but is by far most commonly found in K. pneumoniae and is associ-
ated with the worldwide disseminated sequence type ST 258 (78). In the end of 
1980s, IMP was first isolated from P. aeruginosa in Japan and VIM was first iso-
lated from P. aeruginosa in 1997 in Verona, Italy. Later, both were disseminated 
to K. pneumoniae and other Enterobacteriaceae (79, 80). NDM-1 of Indian origin 
was detected in 2010 and the prevalence rate is very high in Indian subcontinent. 
The prevalence of NDM-producing Enterobacteriaceae in Indian and Pakistani 
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hospitals is ranging from 5 to 18.5%. NDM is also found in drinking water and 
seepage samples in New Delhi (59). As NDM is also found in E. coli, Acinetobacter 
spp and to some extent in P. aeruginosa, there is a high risk of dissemination of 
NDM within the community (81, 82). In 2001, the oxacillinase-type β-lactamase 
(OXA-48) enzyme was first isolated from carbapenem resistant K. pneumoniae in 
Turkey (83). OXA-48 like enzymes have caused outbreaks in UK, France, Germany, 
Belgium and the Netherlands and also disseminated in Northern Africa and the 
Middle East. Still, OXA-48 like enzymes are mostly isolated from K. pneumoniae 
and E. coli but can be found in other species as well (84). 
1.4.3	 Plasmid-mediated	β-lactam	resistance	
Plasmids are circular DNA molecules serving as vectors for transmission of resist-
ance genes and facilitating the spreading of ESBLs. Mobile genetic elements; 
insertion sequences and transposons are acquired by plasmids that mobilize the 
antimicrobial resistance genes. A plasmid can acquire one to several hundreds of 
genes encoding traits such as virulence, antibiotic resistance and metabolic func-
tions. They are advantageous for bacteria but not vital for survival. Plasmids can 
acquire multiple physically linked genetic determinants that confer resistance to 
different classes of antibiotics commonly known as multi-drug resistance (MDR). 
ESBL-producing Enterobacteriaceae (EPE) show co-resistance most commonly 
to fluoroquinolones, aminoglycosides and trimethoprim-sulfamethoxazole (85, 
86). MDR plasmids are self-conjugative, usually large (>50 kb) and encode 
sophisticated mechanisms that control their copy number and regulate the rate 
of replication (87). Plasmid replication is controlled by the replicon; is a DNA 
molecule, replicates from a single origin. Same replicon sharing plasmids cannot 
propagate stably within the same cell, which is the principle of the classification 
of incompatibility groups (Inc). IncFII, IncN and IncI are the predominant groups 
in Enterobacteriaceae (88).
1.4.4	 Plasmid-mediated	non	β-lactam	resistance
In EPE, plasmid-mediated co-resistance to other antibiotic groups are very com-
mon. Most clinically important plasmid-mediated non β-lactam resistance are 
described below.   
Plasmid-mediated aminoglycoside resistance
Production of aminoglycoside modifying enzymes (AMEs) is the most common 
mechanism of aminoglycoside resistance. Aminoglycoside acetyl-transferase 
(AAC (6´)) is the most common AMEs in Enterobacteriaceae. In general, AAC 
(6´) expression confers resistance to both amikacin and gentamicin (89). Plasmid-
mediated 16S rRNA methylase exhibits resistance to aminoglycoside antibiotics 
including gentamicin, amikacin and tobramycin. The most prevalent 16S rRNA 
methylase-encoding genes are armA, rmtA, rmtC and rmtD (90). 
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Plasmid-mediated quinolone resistance
Plasmid-mediated quinolone resistance gene was first identified from a urine  sample 
with growth of K. pneumoniae in 1998 (91). The qnr gene encoding proteins bind 
with DNA-gyrase or topoisomerase and inhibit the mechanism of quinolones. 
QepA and oqxAB are plasmid-mediated genes that upregulate efflux pumps. The 
presence of qnr does not always confer clinical resistance, which has also been 
reported previously (92). 
Plasmid-mediated colistin resistance
The first report of plasmid-mediated colistin resistance due to the mcr-1 gene 
came from China in November 2015 (93). Chromosomally mediated colistin 
resistance gene has also been found in EPE. Changes of charge in lipid A due 
to modification by the enzyme MCR-1, encoded by  gene mcr-1 contributes to 
less interaction with polymyxin. The mcr gene was found in E. coli isolates from 
animals, food and patients. E. coli isolate harboring mcr-1 has been reported for 
co-resistance of CTX-M-55 and an AmpC. Co-resistance was reported after one 
month of the first detection and the isolate was identified from blood samples in 
Denmark. In imported chicken meat, mcr-1 was also reported (94). In our project 
III, we detected mcr-1 for the first time in Sweden from a tourist travelling to 
Thailand. No gastrointestinal symptoms nor intake of antibiotic during the trip 
was reported. Later, another five cases of identification of mcr-1 genes have been 
reported by the Public Health Agency, Sweden (95). It is too early to predict the 
future impact of mcr-1 but the gene is able to transfer into rapidly disseminating 
epidemic EPE isolates such as E. coli ST131 and K. pneumoniae ST512 (96). 
Recently, mcr-1 has been identified from a KPC producer from wound sample 
(97). Moreover, one clonal outbreak of K. pneumoniae ST45 carrying mcr-1 and 
blaKPC-3 was reported from Portugal with 16 cases (98). To date eight variants (mcr-
1-8) have been reported  (96, 99, 100). The clinical significance of CPE acquiring 
mcr-1 could be life threatening due to the risk of total lack of effective antibiotic 
treatment against such infections.   
1.5 Detection of EPE 
ESBL-producing Enterobacteriaceae detection and characterization is mandatory 
for clinical laboratories for infection control purposes. According to CLSI and 
EUCAST, detection of ESBL mainly consists of two phases. At first,  samples 
are subjected to screen for reduced sensitivity to certain antibiotics such as cefo-
taxime, ceftriaxone, ceftazidime and cefpodoxime. Then a confirmatory test 
is performed with the positive screening samples. According to the guidelines 
issued by EUCAST and CLSI, >1mg/L is a screening breakpoint for cefotaxime, 
 ceftriaxone, ceftazidime and cefpodoxime, described in detail in Table 3 (101, 
102). The most sensitive indicator for detection of ESBL is cefpodoxime, which 
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can be used for screening. Combination of cefotaxime and ceftazidime is more 
specific than cefpodoxime alone (103, 104). ESBL screening can be performed 
by using automated system such as VITEK 2 (bioMérieux), Microscan (Siemens), 
Phoenix (Becton-Dickinson) and classical disk diffusion methods. 
Table 3. Screening methods for ESBL-producing Enterobacteriaceae from EUCAST101.
Method Antibiotic Screening positive
Broth or agar dilution Cefotaxime/ceftriaxone and 
ceftazidime
MIC >1 mg/L for either agent
Cefpodoxime MIC >1 mg/L
Disk diffusion Cefotaxime (5 µg) or
Ceftriaxone (30 µg)
And Ceftazidime (10 µg)
Inhibition zone < 21mm
Inhibition zone < 23mm
Inhibition zone < 22mm
Cefpodoxime (10 µg) Inhibition zone < 21mm
1.5.1 Phenotypic confirmation methods
According to EUCAST guidelines, following phenotypic methods are recom-
mended based on the in vitro inhibition of ESBL activity by clavulanic acid for 
ESBL confirmation such as the combination disk test (CDT), the double-disk 
synergy test (DDST), the ESBL gradient test,  broth microdilution test and color-
imetric test (101, 105, 106). 
Combination disk testing (CDT) is performed by adding a disk or tablets containing 
cephalosporin alone (cefotaxime, ceftazidime, cefepime) and in combination with 
clavulanic acid. The inhibition zone around the disk or tablet with cephalosporin 
alone and with clavulanic acid is measured. The test is interpreted as positive if the 
inhibition zone diameter around the cephalosporin with clavulanic acid is ≥5 mm 
larger than the cephalosporin alone (107).
Double-disk synergy test (DDST)
This test is performed by applying cephalosporins (cefotaxime, ceftazidime, 
cefepime) containing disks to plates next to a disk with clavulanic acid (amoxicillin-
clavulanic acid). The results can be considered as positive if the inhibition zones 
around any of the cephalosporin disk are enhanced towards the disk containing 
clavulanic acid. The distance between the disks is important, for cephalosporin 
30µg disk 20mm (centre-to-centre) is optimal. 
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Gradient test method
The Etest ESBL (bioMérieux) is a commercial kit available to perform ESBL 
confirmation test. The reading and interpretation can be performed according to 
manufacturer’s instructions. The test is considered as positive if ≥ 8 fold reduc-
tion is found in the MIC of the cephalosporin plus clavulanic acid, compared with 
the MIC of the cephalosporin alone, or if a deformed ellipse or phantom zone is 
present. If the strip cannot be read due to growth exceeded to the MIC range of 
the strip, then the result is considered as indeterminate. The result is considered 
as negative in all other cases. The gradient test is not reliable for determining the 
MIC but can be used for confirmation of ESBL only.
Broth microdilution
Broth microdilution can be performed by using Mueller-Hinton broth containing 
two-fold serial dilution of cefotaxime, ceftazidime and cefepime at concentrations 
ranging from 0.25 to 512 mg/L with and without clavulanic acid at a concentration 
of 4 mg/L. Bacterial suspension is added to the each well of the microtitre plate 
and then incubated at 37°C for 18 to 24 hours. The test is considered as positive 
if a ≥ 8 fold reduction is found in the MIC of the cephalosporin plus clavulanic 
acid compared to the cephalosporin alone. 
Biochemical (colorimetric) tests
In 2012, the ESBL NDP test was described for the first time. This test was per-
formed by using cefotaxime as indicator antimicrobial and tazobactam as inhibitor 
(108). This test can be performed in 96-well plates or in separate tubes. The test 
will be considered as positive if the colour changes from red to yellow. It has been 
reported that the test was performed directly on patient samples (109).
Another, colorimetric test is β-LACTA test which can be carried out by using a 
chromogenic cephalosporin substrate (HMRZ-86). This test can be performed on 
isolates and also directly on clinical samples. An excellent sensitivity and specificity 
for E. coli and K. pneumoniae (96% and 100%, respectively) have been reported 
by a multicentre study conducted in Belgium and France (110).
1.5.2 Genotypic confirmation
Phenotypic confirmation test is not able to identify specific enzymes causing the 
production of ESBL. Genotypic confirmation is important and can be performed 
by using polymerase chain reaction (PCR), Eazyplex, ESBL gene sequencing or 
DNA microarray. Check-Direct ESBL Real-time PCR (Check-Points, Wageningen, 
The Netherlands) can be used for ESBL detection. 
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1.6 Carbapenemases detection
1.6.1 Phenotypic detection methods
Most clinical microbiology laboratories are using established phenotypic methods 
such as combination disk test, biochemical tests, spectrophotometry, matrix-assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF), and 
lateral flow assays for detection of carbapenemases. Phenotypic detection consists 
of two steps; screening and confirmation. 
Screening of carbapenemases
Chromogenic media is used for screening of carbapenemase-producing Entero-
bacteriaceae from fecal samples. Chromogenic media contains chromogen that 
act as substrate for species-specific enzymes and changes colour due to degrada-
tion. Species can be identified by the colour of the colonies (111). CHROMagar 
KPC (bioMérieux, France) is a commercial chromogenic media that can detect 
VIM and KPC carbapenemases efficiently but OXA-48 with poor sensitivity 
(112).  The highest sensitivity 76% and specificity 75% has been reported for 
CHROMagar KPC (113, 114). Another chromogenic media, BrillianceTM CRE 
contains carbapenem and two chromogens can detect carbapenemase-producing 
K. pneumoniae with higher sensitivity (98%) and specificity (79%) than other 
members of the Enterobacteriaceae. An overall sensitivity of 92% and specificity 
of 85% has been reported (111, 113-115). SUPERCARBA is a nonchromogenic 
media which can detect all class of carbapenemases with higher sensitivity and 
specificity than CHROMagar KPC. The sensitivity of detection of class A, B and 
D carbapenemases were 100, 90 and 100% respectively (113). Remel SpectraTM 
CRE (Thermo Fisher Scientific, Basingstoke, UK) is another type of chromo-
genic media having slightly higher sensitivity (97.8%) and specificity (86.4%) 
than CHROMagar KPC. One day of incubation time is required to obtain result, 
which is the main disadvantage of these media. In certain strains false negative 
results can be obtained due to absence of chromogen-specific enzymes (116). In 
these cases, disk diffusion cut-off for meropenem (<28 mm) and ertapenem (<25 
mm) defined by EUCAST for screening of carbapenemaes in clinical isolates can 
be used (117). Screening of clinical isolates; blood isolates or urine isolates can 
be performed by disk diffusion method. 
Confirmation of carbapenemases
Combination disk test
The commercial version of combination disk test is available from several manu-
facturers. MAST, in UK and Rosco, in Denmark were first to introduce the com-
mercial combination disk test (118-120). Meropenem and various inhibitors are 
combined within the disk or tablets. Class A carbapenemases are inhibited by 
boronic acid, class B carbapenemases are inhibited by dipicolinic acid (DPA) 
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and ethylenediaminetetraacetic acid (EDTA). Avibactam can inhibit OXA-48 
 carbapenemase (121). Cloxacillin, AmpC β-lactamase inhibitor has also been 
added to the test. Cloxacillin, can differentiate between AmpC hyperproduction 
plus porin loss and carbapenemase-production. 
Biochemical tests
Carba NP and CarbAcineto tests are commonly known as biochemical test  having 
high sensitivity and specificity compared with culture-based methods. Turn-around 
time is also faster than with the culture-based methods. Nordmann and colleagues 
developed Carba NP and CarbAcineto tests for the first time in 2012 to identify 
carbapenemase producers in Enterobacteriaceae, Pseudomonas spp. And A. bau-
mannii. The basic principle of these tests is the hydrolysis of imipenem, with a 
change of colour of a phenol indicator from red to yellow due to acid production 
from imipenem hydrolysis. High (100%) sensitivity and specificity of Carba 
NP test has been reported in many studies conducted on Enterobacteriaceae 
and Pseudomonas spp (122) (123, 124). A commercial version of Carba NP test 
RAPIDEC® CARBA NP is available (125). 
The Blue-Carba test (BCT) is another type of biochemical test for rapid (<2 h) 
carbapenemase detection. The principle of the test is based on hydrolysis of imi-
penem by bacterial colonies which can be detected by changes in pH. Presence of 
a carbapenemase will change colour of the pH indicator bromothymol blue from 
blue to green/yellow or from green to yellow (126, 127). An excellent sensitivity 
for class A and B enzymes but suboptimal sensitivity for OXA-48 enzymes have 
been reported (128). 
Another biochemical test is the β CARBA testTM, which can be performed in 
< 2h. The test can be carried out by mixing 1 to 3 colonies in the reagents. After 
30 min of incubation reading can be carried out. Test results will be considered as 
positive when colour changes from yellow to orange, red or purple. An excellent 
performance of β CARBA testTM for detection of CPE has been reported (127). 
Spectrophotometry
Spectrophotometry is a well-known reference method for identification and dif-
ferentiation of carbapenemases in Enterobacteriaceae using imipenem as substrate, 
but is used to a limited degree in clinical laboratories. Supernatant can be collected 
from sonication and centrifugation of 24 h-culture cell with imipenem. Absorbance 
per minute of imipenem and imipenem with bacterial extract were compared. 
The sensitivity 100% and specificity 98.5% has been reported for this test (129). 
With exception of class D carbapenemases, this test can detect efficiently other 
carbapenemases; VIM, IMP and SIM (129). 
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Matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS)
The MALDI-TOF MS can identify resistance genes, bacterial species and sub- 
species by using expressed proteins (130, 131). Ionized carbapenem and its deg-
radation products can be detected after incubation of carbapenem with extracted 
bacterial proteins for 1-4 h which formed spectra of the carbapenem and its 
degradation products. MALDI-TOF MS can detect carbapenemases with 100% 
sensitivity and specificity (132-134). Incubation time can be reduced by adding 
sodium dodecyl sulphate (SDS) to the bacterial cell culture before incubation with 
the meropenem substrate. Using this modification, NDM-1, VIM-1, KPC, OXA-
48 and OXA-162 in Enterobacteriaceae were detected with 100% sensitivity and 
specificity (130).  
Lateral flow assays
Lateral flow assay, or immunochromatographic assay, has been described for 
detection of OXA-48 like carbapenemase. In this assay epitopes of OXA-48-like 
enzymes can be captured immunologically using colloidal gold nanoparticles 
which is bound to a nitrocellulose membrane within a lateral flow device. In this 
assay specific capture reagents based on monoclonal anti-OXA-48 antibodies  are 
used to detect OXA-48 like enzymes directly (135). This is a rapid assay and it 
takes around 4 minutes to perform the assay. This assay can be performed on both 
clinical isolates and directly on positive blood cultures (136, 137). A recent modi-
fication triplex assay has been reported to detect OXA-48, KPC and NDM (138). 
Recently, one single centre performed a retrospective and prospective evaluation 
study and has reported highly accurate detection of all five major carbapenemase 
families (OXA-48, KPC, NDM, VIM, IMP). This study was based on multiplex 
lateral flow assay in which 296 enterobacterial isolates were examined. Overall, 
100% sensitivity and 95.3 (retrospectively) to 100% (prospectively) specificity 
were reported (139). 
1.6.2 Genotypic methods
Real-time PCR can detect and quantify resistance genes simultaneously by using 
fluorescent probes or dyes. Each gene has unique melting temperature which is 
used to identify specific resistance mechanisms (140). Multiple primers can be 
used to detect several genes simultaneously, commonly known as multiplex PCR. 
In multiplex real-time PCR, amplicon size of the target genes should be differ-
ent for easy identification (141). The GeneXpert® (Cepheid, Sunnyvale, CA) is a 
commercial real-time PCR technique available to detect clinically relevant KPC, 
IMP, VIM, NDM and OXA-48 carbapenemases. Check-MDR Carba assay (Check-
Points) is another commercial real-time multiplex PCR assay to detect KPC, NDM, 
OXA-48, VIM and IMP from rectal and throat swabs. 
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Eazyplex® SuperBug CRE assay (Amplex Biosystems, GieΒen, Germany) is a 
commercially available assay that can detect the CTX-M-1-group and CTX-M-9-
group of ESBLs and VIM (-1 to -37), NDM (-1 to -7), KPC (-2 to 15) and OXA-
48-like (-48, -162, -204 and -244 ) carbapenemases directly from rectal swabs 
and bacterial culture (142). It is a loop mediated isothermal amplification based 
assay. One study evaluted this assay directly on urin samples and reported 100% 
sensitivity and 97.9% specificity (143). 
1.7 CRISPR/Cas9 mediated optical DNA mapping
Optical mapping is a process of visualizing individual DNA molecules long range 
sequence information at kbp level. In this process, sequence specific labeled 
DNA can be imaged after stretching using a fluorescence microscope (Figure 3). 
Using optical DNA mapping we can study read lengths of DNA, it can be up to 1 
Mbp, we can also extract information from single molecules and avoid averaging 
(144, 145). This method was first described by Schwartz et al in 1993, restriction 
enzymes were used to cut the DNA molecules at specific sites and the length of 
different fragments were visualized in an agarose gel (146). After that, a signifi-
cant advancement has been observed in the field of optical mapping including 
different approaches for stretching and labeling were introduced. Most important 
advancements are stretching of DNA molecules on modified glass surfaces as well 
as nanofluidic devices (147). 
Labeling of DNA molecules can be performed by enzyme based or affinity based 
techniques. Jo et al (148) introduced nick labeling, in this process a nicking enzyme 
was used to generate a single stranded break which is known as nick a 4-7 bp long 
recognition site. Then fluorescently labeled nucleotides were incorporated along 
the strand using DNA polymerase. DNA molecules were stained using YOYO 
to determine start and end of each molecule (148). Using CRISPR/Cas9 based 
approach, a highly adaptable 23 bp recognition site has been reported by McCaffery 
(149). Another way of labeling DNA is competitive binding that has been reported 
recently (150, 151). In this process AT specific non-fluorescent molecule netropsin 
and the fluorescent dye YOYO were used simultaneously. Both molecules will 
compete for binding site on DNA molecules. If we use accurate concentration, 
netropsin will bind to AT-site and prevent YOYO to bind to AT-site and YOYO will 
bind to GC-site. So, GC rich region will be bright and AT rich region will be dark. 
This process was used to characterize plasmids in the fourth project of this thesis. 
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Figure 3.	Schematic	diagram	of	optical	mapping	from	paper	IV.	Rights	to	reprint	from	
MBio. 
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2 AIMS
The overall aim of this thesis was to investigate the clonality and proportion of 
ESBL-producers in K. pneumoniae from patients with bloodstream infections, 
and to study acquisition of EPE in healthy Swedish travellers travelling to high 
prevalence region of EPE. A second major aim was to evaluate rapid detection and 
characterization methods for EPE and CPE. 
Specific aims
I) To characterize clinical isolates of Klebsiella pneumoniae and investigate 
the association with phylogroups, virulence factors and mortality during 
bloodstream infection (BSI) (Paper I)
II) To evaluate a commercial method the RAPIDEC CARBA NP test for detection 
of carbapenemase-producing Enterobacteriaceae, Pseudomonas aeruginosa 
and Acinetobacter spp (Paper II)
III) To identify bacterial colonizing characteristics that play key role for travellers 
to become carriers of ESBL-producing Enterobacteriaceae (EPE) (Paper III)
IV) To characterize risk factors for acquiring EPE in the intestinal microbiota 
during travel (Paper III)
V) To characterize resistance plasmids during an outbreak with an ESBL-
producing strain of K. pneumoniae using optical DNA mapping, and further 
investigate whether the plasmid was transferred to ESBL-producing E. coli 
during outbreak (Paper IV)
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3 MATERIALS AND METHODS
3.1 Sample collection
In Paper I, we studied a total of 139 isolates of K. pneumoniae (blood n=137, or 
cerebrospinal fluid n=1, or both n=2). All isolates were obtained from 139 adult 
(≥ 18 years old) patients admitted to Karolinska University Hospital, Solna during 
the years 2007 to 2009. In Paper II, we studied a total of 276 clinical isolates of 
Gram-negative bacilli. Detailed strain collection can be found in Table 4. Karolinska 
University Laboratory (KUL) and Publich Health England’s (PHE) Antimicrobial 
Resistance and Healthcare Associated Infections (AMRHAI) reference Unit jointly 
performed this study. In Paper III, we studied a total of 188 healthy adults (≥ 18 
years old) Swedish travellers travelling to highly EPE prevalent regions; Southeast 
Asia, Indian subcontinent, North Africa and the Middle East. We collected rectal 
swabs and survey data from 188 healthy Swedes travelling to the above-mentioned 
four high EPE prevalence regions. This study was performed at the Department 
of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden. Rectal 
swabs were collected before and after the trip. Travellers, who did not provide 
both samples were excluded from the study. In Paper IV, we studied fecal samples 
from 17 neonates during an extended-spectrum β-lactamase (ESBL)-producing 
Enterobacteriaceae (EPE) outbreak at the NICU at Karolinska University Hospital 
in Stockholm, Sweden November 2008 and March 2009 which has been published 
previously (152). During follow-up, we collected fecal samples every second 
month from 14 surviving neonates from discharge to two years of age. We also 
conducted a five years’ follow-up on 10 neonates due to drop-outs. 
3.2 Ethical considerations
In this thesis, we used patient and human samples in project I, III and IV. We also 
used clinical data for analysis. We obtained ethical approval from the Karolinska 
Institutet Regional Ethics Committee of Stockholm for project I (Paper I) (recordal 
2009/1985-31/4) and for project III (Paper III) (recordals 2013/1844-32 and 
2015/1620-32). We also obtained ethical approval from regional ethical review 
board in Stockholm, Sweden (2009/734-31/4 and 2014/491-31/3) for project IV 
(Paper IV). No ethical approval was required for project II (Paper II) as the 
study was conducted on clinical strains. Moreover, no clinical data was used for 
analysis in project II. 
The committee approved that we did not need to collect any written or verbal 
consent for project I from the study subjects as the study was conducted on large 
number of patients (n=139) and a large number of patients were died before the 
start of the project. It would not be possible to carry such a study where mortality 
has been analysed if written or verbal consents were required. Moreover, only 
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limited clinical data were used anonymously in this study. We collected written 
consent from study subjects for project III. To pursue research project III and IV, 
most important ethical considerations is emotional impact of study participants. 
When study participants get to know that they are carrier of antibiotic resistant 
bacteria some may get psychological reactions and feel worried about being an 
asymptomatic carrier and which consequences this could have in the future. It is 
important to provide information to the participants about the implications of being 
a carrier, and to offer expert consultations to allow the individual to ask questions 
about fecal carriage and its implications. 
3.3 Species identification and susceptibility testing 
Species were identified by using VITEK2 (bioMérieux, Marcy-I’Etoile, France) 
in project I & IV and MALDI-TOF Biotyper (Bruker, Billerica, MA, USA) in 
project III. 
In project I and III, antimicrobial susceptibility testing was carried out with the 
disk diffusion method on Isosensitest agar (Oxoid, Basingstoke, UK). The inter-
pretation was performed following the guidelines of Swedish Reference Group 
for Antibiotics (SRGA) in project I and EUCAST guidelines were followed for 
interpretation in project III (117) (153). In project II, antimicrobial susceptibility 
was performed using meropenem and ertapenem disk by disk diffusion method and 
interpretation was performed following EUCAST guidelines at KUL. At AMRHAI, 
BSAC agar dilution with AMRHAI’s standard Gram-negative antibiotic panel; 
ertapenem, imipenem and meropenem was used for susceptibility testing. BSAC 
breakpoints were used for interpretation. 
3.4 ESBL Screening and subtyping
ESBL- and/or carbapenemase-producing isolates were investigated using Check-
MDR (Checkpoints, Wangeningen, The Netherlands) in project I. In project 
III, screening of EPE was performed using ChromID ESBL agar (bioMérieux, 
Marcy-I’Etoile, France). Further, broth enrichment was performed using LB broth 
(Thermo Fisher Scientific, Waltham, USA) for all samples (n=188) and cultivated 
on an in-house agar on a chromogenic base (Liofilchem, Roseto degli Abruzzi, 
Italy) supplemented with 200 mg/L cloxacillin and 0.25 mg/L meropenem for an 
overnight incubation at 35°C. VITEK2 (bioMérieux, Marcy-I’Etoile, France) was 
also used for ESBL testing. Using Check-MDR (Checkpoints, Wageningen, The 
Netherlands) we performed ESBL subtyping and Diversilab, an automated rep-
PCR system, was used for epidemiological typing.  
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3.5 Phenotypic and molecular detection of 
carbapenemase
In project II, RAPIDEC® CARBA NP (bioMérieux SA, Marcy l’Etoile, France) 
was used for phenotypic detection of carbapenemase producers. We followed the 
manufacturer’s protocol, in brief: isolates were cultivated on Muller Hinton E agar 
for 18-24 hours. Incubation of RAPIDEC® CARBA NP tests were 30  minutes 
to two hours at 37°C. Reading was performed by visually comparing colours 
between test well and control well. Change of colour of the test well from red to 
yellow or orange was interpreted as positive. In case of positive result, incubation 
was stopped after 30 minutes otherwise continued to two hours before a negative 
result was interpreted. 
In-house real-time or conventional PCR assays were used for molecular detec-
tion of carbapenemases. PCR primers were used to target the following groups of 
carbapenemases; KPC, NDM, VIM, OXA-23, OXA-24, OXA-48, OXA-58, IMP, 
GIM, SIM, SPM, GES, IMI and SME. We used antimicrobial  susceptibility profile 
instead of PCR for rarely occurring carbapenemases for all isolates (154-162). 
False-positive isolates were further investigated using whole-genome  sequencing 
(WGS) using a HiSeq sequencer (Illumina, Little Chesterford, UK). In-house bio-
informatics pipeline was used for data analysis. We determined the presence of 
resistance genes according to previously described methods (163). 
3.6 Serotyping and virulence and resistance gene 
detection
In project I, detection of serotypes and virulence genes were performed using 
real-time PCR according to previously described methods (164, 165). Community-
acquired invasive disease has been  associated with six major serotypes; K1, K2, 
K3, K4, K5, K6 and three virulence genes allS, rmpA, wcaG of K. pneumoniae, 
which were all investigated (166, 167). Six serotypes and three virulence genes 
specific primers were used for real-time PCR. In project III, we also investi-
gated virulence factors and resistance genes using real-time PCR. PCR primers 
were specific for fimAMT78, fimH, papAH, papC, papEF, and papG allele I, II, 
III and armA, rmtA, rmtB, rmtC, rmtD, qnrA, qnrB, qnrC, qnrD, qnrS. We also 
investigated the presence of plasmid-mediated fluoroquinolones resistance gene 
aminoglycoside-(6)-N-acetyltransferase (aac(6’)-Ib) and its point mutant aac(6’)-
Ib-cr using real-time PCR following previously published protocol (168, 169). 
We also investigated plasmid-mediated colistin resistance gene mcr-1 against all 
isolates following previously published protocol (93). One isolate that carried 
the plasmid-mediated colistin resistance gene mcr-1 was further analysed using 
Next-generation sequencing technology the Ion Torrent S5 XL system (Themo 
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Fisher Scientific, Waltham, MA, USA). The presence of plasmid-mediated colistin 
resistance gene mcr-1 was confirmed by analyzing with ResFinder (170). We also 
confirmed the ST for this isolate following previously described method (171). 
Plasmid type was confirmed by using PlasmidFinder (172). All isolates of E. coli 
in project III were subjected to phylogrouping using real-time PCR following 
previously described protocol (29). 
3.7 Phylogenetic analysis
In project I, we performed seven house-keeping genes based MLST for phylo-
genetic analysis of all isolates according to previously published methods (166, 
173). Seven house-keeping genes were amplified and sequenced using primers 
and protocol, can be found on the web site (htt://bigsdb.web.pastur.fr). We deter-
mined  nucleotide sequences for seven house-keeping genes by using ABI Prism 
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). We obtained allelic 
and sequence type numbers by direct comparison with the K. pneumoniae MLST 
database (htt://bigsdb.web.pastur.fr). In case of new allele and ST, numbers were 
assigned by curator of the K. pneumoniae MLST database. All sequences were 
aligned by using Mega V5 (174). We identified phylogroups using Neighbor-joining 
trees based on concatenate sequences of all seven MLST loci for all isolates. We 
used three reference strains; ATCC13883 for phylogroup KpI: K. pneumoniae, SB59 
for phylogroup KpII: K. quasipneumoniae and Kp342:ST146 for phylogroup KpIII: 
K. variicola to identify phylogroups (175). We confirmed phylogroups separately 
by using Neighbor-joining trees based on each allele. We also used Splits Tree v4 
(176) for NeighborNet analysis to confirm phylogroups and recombination events. 
Nucleotide diversity of each gene for each phylogroup and for all isolates were 
calculated by using DnaSP (177). With the help of BioNumerics v7.0 (Applied 
Maths, Sint Maartens-Latem, Belgium), we produced minimal spanning tree (MST) 
(178). Isolates sharing six loci of their allelic profiles with one another member 
of the group were defined as clonal complexes. We identified clonal complexes 
by using eBURST V3 (179). 
3.8 Clinical data
In project I, we retrieved medical data for finding association between phylo-
groups, 30-day mortality, patient risk factors, hospital versus community-acquired 
infections and antibiotic treatment.  Assessment of comorbidity was performed by 
constructing Charlson comorbidity index (180). In case of more than one species 
were identified from specimens obtained within 24 hours from K. pneumoniae 
bloodstream infection were considered as polymicrobial infection. If the patient 
had been to hospital more than 30 days or if the sample was taken >48h after admit-
tance, the episode was defined as hospital-acquired. In project III, study subjects 
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returned a filled questionnaire based on personal information and potential risk 
factors such as underlying chronic diseases, duration of travel, antibiotic treat-
ment during travel, getting treatment from local healthcare before and after travel. 
3.9 Plasmid characterization
In paper IV, we conducted bacterial plasmid characterization based on optical DNA 
mapping (Figure 3). We utilized the emission intensity variation along the DNA 
by adding fluorescent YOYO-1 and the non-fluorescent AT-selective  netropsin, 
where AT-rich regions are dark and GC-rich region are bright. Visualization of 
the variation of emission intensity, the DNA barcode can be retrieved by stretch-
ing single intact plasmids in nanochannels and imaging them using fluorescence 
microscopy. Previously, it has been demonstrated that the method can measure 
the number and size of all large plasmids in a bacterial cell. It has also been dem-
onstrated that it can produce a unique barcode for each plasmid which can later be 
used to identify conjugation of plasmids between different strains and species of 
bacteria. Latest improvement of the assay was done by adding the CRISPR/Cas9 
system, now the method is able to demonstrate a specific (resistance) gene har-
bouring plasmid. Plasmids were extracted from 100 ml overnight bacterial cultures 
in LB broth by using the Macherey-Nagel NucleoBond Xtra Midi preparation kit 
according to the manufacturer’s instructions. We precipitated eluted plasmid DNA 
into iso propanol and resuspended it in 1 × TE buffer. Then, we treated plasmid 
with Cas9 and guide-RNA (gRNA) targeting blaCTX-M group 1 gene according 
to our previously published protocol (181). To obtain DNA barcode, we stained 
plasmid and λ-DNA (New England Biolabs) at equal concentration with YOYO-1 
(Invitrogen) at a molecular ratio of 1:2 (YOYO-1:bp) and with netropsin (Sigma-
Aldrich) at a molar ratio of 100:1(netropsin:YOYO-1). Here, we used λ-DNA 
for internal size marker (48 500 bp). To obtain uniform staining, we incubated 
plasmid DNA (2μM) with YOYO-1 and netropsin in 10 μl of 0.5X TBE at 50°C 
for 30-60 min (182). We used Millipore water to dilute samples in order to obtain 
a final concentration of 0.05X TBE and 0.2 μM (bp) of DNA. We added 2.5% 
(v/v) β-mercaptoethanol (BME) to the solution to supress photo nicking and photo 
bleaching of DNA molecules. We fabricated nanofluidic channels in oxidized 
silicon, according to previously described methods (183). DNA molecules were 
stretched through nanochannels of dimensions 100 nm x 150 nm2 and a length of 
500 μm. We cleaned nanochannels with 5% w/w sodium hypochlorite solution and 
then washed a few times with loading buffer (0.05x TBE) before loading samples. 
This process enhanced the usage of nanofluidic chips more than 50 times. On 
average we used chips in each section at least 10 times. We placed 15μl of DNA 
solution to the reservoir and we used nitrogen gas to force DNA molecules into 
nanochannels. To image DNA molecules we used an inverted microscope (Zeiss 
AxioObserver.Z1) equipped with either a 63x (with 1.6 times optovar) or 100x 
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oil immersion objective (Zeiss, NA=1.46) and an EMCCD camera (Photometrics 
Evolve or Andor iXon). We imaged both circular or linear molecules for 200 frames 
with 100ms exposure by stretching into the nanochannels. 
We analyzed data to identify the number of plasmids in each sample, their cor-
responding size, their sequence-specific barcode and possible location of a resist-
ance gene (blaCTX-M group 1). In brief, we used the internal size marker λ-DNA to 
calculate the plasmid size. We also used conversion factor 1.8 to estimate whether 
directly from linearized plasmids, or from plasmids in their circular form (184). 
We compared linear fragments of similar size (+/- 10%), acquired either by Cas9 
linearization, or via extensive light exposure (185). High degree of similar individual 
barcodes (typically Pearson Cross Correlation (CC) > 0.75) were merged into a 
consensus barcode to compare between different isolates, rendering a p-value (186). 
We studied the position of the double strand-breaks of the individual plasmid bar-
codes and the consensus barcode to detect the presence of a resistance gene (181). 
Qiagen Genomic-tip 100 kit was used to extract complete genomic DNA (chromo-
somal DNA and plasmids) according to the manufacturer’s instructions. Long read 
sequencing was performed using PacBio Sequencing technologies in collaboration 
with Science for Life Laboratory in Uppsala on a RSII system with one SMRT cell 
per genome. Sequencing library was prepared using Illumina MiSeq sequencing 
with two times 300-bp paired-end read lengths and Nextera XT DNA Library 
preparation kit (Illumina) following manufacturer’s instructions. Overall generated 
chromosomal coverage was >25-fold for all isolates. The CLC Genomics work-
bench v.10 (CLC Bio, Aarhus, Denmark) including the CLC Microbial Genomics 
Module 3.0 was used to perform de novo assembly for each data set. Illumina reads 
were assembled using contig sequences from the PacBio sequencing as references. 
The resulting contigs were analyzed by mate-pair analysis and circularized by 
detection of redundant end-sequences. De novo assembly of non-matched reads 
from combined reference assemblies for each dataset was performed to verify that 
no plasmids were missed between isolates. Remaining contigs were analyzed for 
gene content by using BLASTn searches. Complete genome annotation was per-
formed by using the NCBI Prokaryotic Genome Annotation Pipeline. ResFinder, 
PlasmidFinder, and VirulenceFinder, were used to detect resistance genes, plasmid 
replicons and virulence genes respectively (170, 172, 187). 
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4 RESULTS
4.1 Paper I
The aim of this study was to determine association between phylogroups, virulence 
factors and mortality in clinical isolates of K. pneumoniae causing BSI. Three dis-
tinct phylogroups were disclosed by phylogenetic analysis by multilocus sequence 
typing (MLST). The most predominant phylogroup was phylogroup KpI (corre-
sponding to K. pneumoniae n = 96) followed by phylogroup KpIII (corresponding 
to K. variicola n = 34) and phylogroup KpII (corresponding to K. quasipneumo-
niae n = 9) (Figure 4). The highest mean genetic distance among phylogroups was 
4.5% (KpII-KpIII), followed by 4.4% (KpI-III) and 4.0% (KpI-KpII). Thus, we 
observed that phylogroups KpI-KpII are more closely related compared to phylo-
group KpIII. Neighbor-joining tree analysis also supported three phylogroups and 
suggested a high level of recombination within each group, as well as between 
the phylogroups. We also observed minor events of insertion/deletion (INDEL) 
in the tonB locus by aligning seven housekeeping genes. Considering all isolates, 
highest polymorphic sites were observed in tonB 19.6% and lowest polymorphic 
sites were observed in gapA 5.1% (Table 5) whereas only 10.7% polymorphic sites 
were observed in concatenate sequence. Average nucleotide diversity Π of 2.1% 
was observed for the whole population, whereas Π was much lower within the 
phylogroups; KpII (1.3%), KpI (0.37%) and KpIII (0.63%). The ratio of the number 
of non-synonymous substitution per non-synonymous site (Ka) to the number of 
synonymous substitution per synonymous site (Ks) was observed to be less than 
one, which indicated that housekeeping genes were evolved predominantly under 
purifying selection. An extensive haplotypic diversity with 116 distinct STs was 
observed by the MLST based population analysis. The clonal relatedness among 
sequence types (STs) were analysed using both MLST and eBURST method. A 
total of 48 isolates comprised 12 clonal complexes and remaining 91 isolates split 
into 79 singletons (STs that differed by two or more alleles from another ST). 
Only 18 strains of 139 isolates were serotypable for tested capsular serotypes; 
K1, (1.4%; 2/139), K2 (5.0%; 7/139), K20 (1.4%; 2/139), K54 (2.2%; 3/139) 
and K57 (2.9%; 4/139). The predominant serotype was K2, whereas K5 was not 
found in any isolates. A total of 16 out of 18 capsular types were associated with 
phylogroup KpI and the remaining 2 were associated with KpIII. In this study 
virulence gene wcaG 8.6% (12/139) was the most frequently detected virulence 
gene followed by allS 4.3% (6/139) and rmpA 3.6% (5/139). A total of 8 (5.8% 
8/139) isolates exhibited mucoid phenotype and among them two isolates were 
also positive for rmpA. The distribution of isolates harboring virulence genes were 
KpI (n=13), KpIII (n=5) and KpII (n=3). 
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A total of 17.3% (24/139) with 30-day mortality was observed. Isolates belonging 
to phylogroup KpIII were highly associated with the highest 30-day mortality of 
29.4 % (10/34 cases), whereas isolates belonging to phylogroup KpI and KpII were 
associated with 30-day mortality of 13.5% (13/96 cases,) and 11.1% (1/9 cases), 
respectively. Out of the 24 events associated with 30-days mortality, only one was 
serotypable (K54) and one exhibited mucoid phenotype and/or (wcaG n=1 and 
wcaG/allS n=1). We observed low level of antibiotic resistance in general but the 
highest resistance rate 10.8% was observed against trimethoprim/sulfametoxazole 
followed by ciprofloxacin 8.6%, piperacillin/tazobactam 5.8%, gentamicin 3.6%, 
ceftazidime 4.3% and cefotaxime 3.6%. Isolates of KpI were more resistant against 
trimethoprim/sulfametoxazole compared to KpIII isolates. K. variicola (KpIII) 
isolates were found to be less resistant than isolates of K. pneumoniae (KpI) and 
K. quasipneumoniae (KpII) for several classes of antibiotics. 
Figure 4. Phylogenetic analysis based on Neighbor-joining trees (A), Minimal spanning 
tree (MST) (B), and NeighborNet analysis (C). Sequence type is represented by each circle. 
Black lines between STs indicate that they differ in one allele (thick lines), two and three 
alleles	(thin),	or	four	to	seven	alleles	(dashed).	Rights	to	reprint	from	PLoS	One	(Paper	I).	
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Table 5. Nucleotide diversity within seven housekeeping genes. N = number of  samples 
subjected for analysis. Sites = Length of sequence after alignments. Net Site = Length of 
sequence subjected for analysis. S = polymorphic sites. Hap = haplotypes. Hd = haplotypic 
diversity. Π = nucleotide diversity. θ = average number of nucleotide difference per site.  
Ka/Ks = ratio of the number of non-synonymous substitution per non-synonymous site (Ka) 
to the number of synonymous substitution per synonymous site (Ks). Rights to reprint from 
PLoS One (Paper I). 
Alleles n Sites NetSites S Hap Hd Π θ Ka/Ks
gapA 139 450 450 23 18 0.692 0.00819 0.009683 0.0995
infB 139 318 318 28 19 0.756 0.01522 0.017127 0
mdH 139 477 477 59 26 0.805 0.02797 0.023598 0.0324
pgi 139 432 432 54 28 0.693 0.02405 0.023955 0.0144
phoE 139 420 420 41 41 0.939 0.01401 0.020316 0.0064
rpoB 139 501 501 41 27 0.815 0.01447 0.015582 0.023
tonB 139 438 402 79 47 0.952 0.04667 0.040646 0.0693
Concatenate, 
Total 139 
strains
139 3 036 3 000 325 115 0.996 0.02138 0.021363 0.0344
Concatenate, 
KpI
96 3 024 3 006 115 75 0.993 0.00371 0.007448 0.0778
Concatenate, 
KpII
9 3 018 3 012 105 9 1 0.0132 0.012949 0.02
Concatenate, 
KpIII
34 3 018 3 006 155 31 0.995 0.00637 0.012936 0.0125
4.2 Paper II
We have evaluated a commercial version of RAPIDEC® CARBA NP against a 
total 276 Gram-negative bacilli consisting of (n=138) carbapenemase producers 
and (n=138) non-carbapenemase producers.  A total of 135 isolates (97.8%) were 
correctly identified as carbapenemases producers using RAPIDEC® CARBA NP 
assay. One OXA-48-producing K. pneumoniae, one OXA-23 and one OXA-24-
producing Acinetobacter baumannii were not detected in RAPIDEC® CARBA 
NP assay. Similarly, RAPIDEC® CARBA NP assay confirmed 135 (97.8%) nega-
tive isolates those were previously carbapenemases negative. One Pseudomonas 
aeruginosa with OprD loss and efflux, one ceftazidimase-producing Klebsiella 
oxytoca and one Enterobacter cloacae with impermeability were false positive in 
RAPIDEC® CARBA NP assay. Whole genome sequencing (WGS) was used to 
further analyse the three false positive isolates and known carbapenemases were 
absent in P. aeruginosa and E. cloacae. However, WGS analysis confirmed the 
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presence of the carbapenemase GES-5 in K. oxytoca, confirming that the positive 
result in the RAPIDEC® CARBA NP assay was in fact correct. After adjustment 
of GES-5 producer, overall sensitivity of the RAPIDEC® CARBA NP test was 
97.8% and specificity was 98.5% (Table 6).
Table 6. Analytical sensitivity and specificity of RAPIDEC® CARBA NP test. Rights to 
reprint from JAC (Paper II).
Sensitivity 
%
Specificity 
%
True 
positive
True 
negative
False 
positive
False 
negative
Isolates 
tested
Carbapenemase-
producing isolates 
(overall)
97.8 - 139
Carbapenemase-
producing 
Enterobacteriaceae 
(overall)
99.1 - 110 0 0 1 111
KPC 100 - 40 0 0 0 40
OXA-48-like 96.3 - 26 0 0 1 27
NDM1 100 - 30 0 0 0 30
VIM 100 - 5 0 0 0 5
IMP 100 - 5 0 0 0 5
IMI 100 - 1 0 0 0 1
GES 100 - 3 0 0 0 3 
Carbapenemase-
producing 
Acinetobacter 
(overall)
86.7 - 13 0 0 2 15
Carbapenemase-
producing 
Pseudomonas 
(overall)
100 - 13 0 0 0 13
Carbapenem S 
or carbapenem R 
isolates without 
carbapenemase 
(overall)
   - 98.5 0 135 2 0 137 
1 Including two isolates with NDM+OXA-48.
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4.3 Paper III
We analysed a total 376 faecal samples from 188 healthy travellers. Thirteen of 
188 (6.9%) were excluded from the analysis, as they were colonized with EPE 
before travel. We identified total 67 different EPE strains from 175 pre-travel 
negative participants. The predominant isolates were E. coli (n=65), followed by 
K. pneumoniae (n=1) and Citrobacter freundii (n=1). Carbapenemases-producing 
Enterobacteriaceae were not detected. Most EPE were of the the CTX-M type 
(61 strains) and most predominant type was CTX-M-1 (n = 49, 73.1%) followed 
by CTX-M-9 (n =12, 17.9%). A total 8 of 12 CTX-M-9-producing strains were 
acquired in South-East Asia (Figure 5). 
Figure 5. Geographical representation of ESBL distribution. Circle size represents to 
colonization	rate.	Rights	to	reprint	from	JAC	(Paper	III).
In 50 (76.9%) E. coli strains, type 1 fimbriae-encoding gene fimH was present, 
whereas fimAMT78 was detected in 15 (23.1%) isolates. Pyelonephritis-associated 
pili-encoding genes were observed in six (9.2%) isolates and all these six isolates 
acquired papEF gene. Five isolates carried additional papC and papGII and two 
isolates harboured papAH gene. All pap harbouring strains were isolated from 
travellers travelling to India. 
32
Phylogroup A (28/65, 43.1%) was the most commonly identified phylogroup, 
followed by phylogroup D (17/65, 26.2%), phylogroup B1 (12/65, 18.5%) and 
phylogroup B2 (8/65, 12.3%). Phylogroups B2 and D isolates were more com-
monly associated with multi-drug resistant (MDR) than the isolates of phylo-
groups A and B1. All isolates were identified as cefotaxime-resistant and 92.5% 
(62/67) isolates were resistant to ceftazidime. In other antibiotic classes, highest 
resistance 58.2% (39/67) was observed against trimethoprim/sulfamethoxazole, 
followed by ciprofloxacin 40.3% (27/67), gentamicin 29.9% (20/67), piperacillin/
tazobactam 22.4% (15/67), amikacin 7.5% (5/67) and ertapenem 6.0% (4/67). A 
total 49.3% (33/67) isolates were detected as MDR strains. A total 46.3% (31/67) 
isolates harboured plasmid-mediated quinolone and fluoroquinolone resistance 
genes [qnr and/or aac(6’)-Ib] and among them most commonly detected gene was 
qnrS, found in 20 isolates followed by aac(6’)-Ib in 10 isolates, qnrB in 4 isolates 
and qepA in 1 strain. Ten out of 24 qnr harbouring isolates were resistant against 
ciprofloxacin. Two isolates harbouring 16S methylase gene rmtB were resistant to 
both gentamicin and amikacin. A CTX-M-55-producing E. coli isolate harbouring 
plasmid-mediated colistin resistance gene mcr-1 was identified for the first time 
in Sweden from one traveler had travelled to Thailand in late 2013. The strain 
had a colistin MIC of 4 mg/L. ResFinder analysis also identified additional two 
aminoglycoside resistance genes [aadA1A2 and aac(3)-IId], one blaTEM-1B and one 
fluoroquinolone resistance gene (qnrS1) in this isolate.     
EPE colonization rates differed with different geographical region. Highest EPE 
colonization was observed in Indian subcontinent (49%) followed by northern Africa 
(44%) and lowest EPE colonization was observed in Turkey (10%) followed by 
Southeast Asia (19%). In agreement with previous studies, we found that  diarrhea and 
antibiotic treatment during the trip were independent risk factors for EPE acquisition 
(OR 5.92), (65, 67, 68). EPE colonization was negatively associated with chronic 
diseases (OR 0.27). Sex, age, duration of trip, intake of proton-pump inhibitors, or 
use of oral cholera vaccine had no significant association with EPE colonization. 
The distribution of phylogroups differed between  geographical regions. Strains 
belonging to phylogroup B2 (n=8) were only identified from travellers to Southeast 
Asia and the Indian subcontinent. 
4.4 Paper IV
Initially, 17 neonates were colonized with blaCTX-M-15 -producing K. pneumoniae 
(ESBL-KP), sequence type ST101. After storage, only 16 strains were viable and 
included in the molecular analysis. Optical mapping results of 16 ESBL-KP ST101 
isolates confirmed that each isolate contained two different plasmids with differ-
ent sizes. The sizes of the plasmids were approximately 80 kbp and 162–222 kbp. 
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Guide RNA was targeted to blaCTX-M- group1 genes which guide the Cas9 to cut at 
the same location of 80 kbp plasmid of all isolates. The location of blaCTX-M- group1 
genes can be seen by using barcodes (Figure 6). Cas9 did not cut the larger plasmid 
which indicates that the larger plasmid did not acquire any blaCTX-M- group1 gene. 
Plasmids were linearized using light-induced DNA breaks to reveal the barcode. 
The size of the larger plasmid varied in different patient isolates, indicating that 
they all originated from same plasmid. All isolates had a large identical region 
(~160 kbp) but deletions were observed in three of the isolates; patient 3 (~5 kbp), 
patient 5 (~55 kbp) and patient 8 (~31 kbp). The deletion locations were clearly 
visible in the barcodes (Figure 6, right). This is how this method explains the vari-
ation in size of different plasmid. Considering these deletions, we confirmed that 
all of the larger plasmids had the same origin (p<0.001). 
Figure 6. Barcodes of different plasmids of ESBL-KP isolates from each of 16 patients. 
Rights	to	reprint	from	MBio	(Paper	IV).	
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ESBL-KP isolates were collected from seven of the patients during the period of 
6-24 months after initial isolation and were further investigated. In six isolates, 80 
kbp plasmids harbouring blaCTX-M-15 gene were present. The 80 kbp plasmids were 
identical with the initial five patients (p-< 0.001), whereas an inversion of about 
31 kbp was present in the small plasmids of patient 6 (Figure 7, dashed region). 
In five out of six isolates, one larger plasmid was completely missing in an isolate 
from patient 4 (Figure 7 right). A region of 5-65 kbp deletions were observed in 
isolates from three patients. Three plasmids with size of 72±3.6, 122±6.3, and 
204±10.2 kbp were observed in the isolate of patient 13 which was collected 9 
months after initial isolate (Figure 7 bottom). No overlap was observed, and no 
blaCTX-M group 1 gene was detected in any of these three plasmids which indicated 
that the ESBL-KP isolate was unrelated to the outbreak. 
Furthermore, genetic characterization of the plasmid content in all ESBL-KP 
samples were investigated using long-read sequencing on the PacBio platform to 
sequence the plasmid from the initial ESBL-KP from patient 1 (P1K0). We com-
pared the barcodes obtained from optical mapping with the theoretical barcodes 
predicted from the PacBio sequencing and found excellent overlap (Figure 8). The 
size of smaller and larger plasmids were 80272 bp and 215872 bp, respectively, 
were determined by PacBio sequencing. Sequence analysis determined that the 
small plasmid 80 kbp contained IncR, and IncFIA origin. In addition to blaCTX-M-15, it 
also contained blaTEM-1, and genes encoding resistance to fluoroquinolones (qnrB1), 
sulphonamides (sul2), trimethoprim (dfrA14) and aminoglycosides (aaac(3)-IId), 
aph(6)-Id, aph(3’’)-Ib). The larger plasmid did not carry any resistance genes. 
Additional ESBL-producing E. coli (ESBL-EC) were found in the follow up sam-
ples. The blaCTX-M-group-1 gene was absent which indicates that ESBL phenotype of 
this isolates had a different genetic origin than ESBL-KP. Approximately, a size 
of 130 kbp identical plasmids were found in ten of the investigated ESBL-EC 
isolates. To validate the optical mapping data, we sequenced isolate P3E6 using 
PacBio and found a plasmid with size of 129 kbp, and a small size of 5,878 bp 
of cryptic plasmid. Resistance genes were absent in all of these plasmids, but the 
sequencing confirmed that blaCTX-M-15 gene was located on the E. coli chromo-
some, which was in accordance with optical mapping results, as there was lack 
of Cas9 cleavage of any plasmids. 
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Figure 7. Comparison between follow up ESBL-KP isolates (black lines) and correspond-
ing	initial	ESBL-KP	ST101	isolate	(gray	lines).	Rights	to	reprint	from	MBio	(Paper	IV).	
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Figure 8. Comparison between experimental optical map (gray) and theoretical optical 
map	created	from	PacBio	sequencing	(black)	for	the	two	plasmids	in	P1K0.	Rights	to	
reprint from MBio (Paper IV).
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5 DISCUSSION
5.1 Major Findings 
In the first project, we wanted to analyze clonal diversity and the prevalence of 
EPE and CPE in invasive isolates of K. pneumoniae isolated from BSI patients 
in a well-defined geographical area and we collected all samples from the depart-
ment of clinical microbiology at Karolinska University Hospital, Stockholm. 
We observed very low prevalence of antimicrobial resistance among Swedish 
bloodstream  infection (BSI) patients. Only five out of 139 isolates were detected 
as MDR (resistant to three or more than three antibiotic classes). All of these five 
isolates were EPE (two isolates CTX-M-1, one isolate CTX-M-1 and SHV, one 
isolate SHV) but only one isolate was a CPE (carbapenemase VIM), CTX-M-1 
and CMYII. Then, we wanted to characterize Klebsiella pneumoniae sensu lato 
isolated from BSI patients to analyze their population structure. We also wanted to 
investigate potential linking between phylogroups, bacterial traits, mortality and 
comorbidity. We observed three distinct phylogroups, the largest phylo group was 
KpI consisting of (n=96) isolates of K. pneumoniae followed by phylo group KpIII 
consisting of (n=34) isolates of K. variicola and phylogroup KpII consisting of 
(n=9) isolates of K. quasipneumoniae. We also observed a high link between 
30-day mortality and K. variicola (KpIII) (29.4%) isolates compared to K. pneu-
moniae (KpI) (13.5%) isolates. Although, K. variicola (KpIII) isolates had low 
virulence and resistance profile compared to K. pneumoniae. We observed several 
comorbidities; malignancy, diabetes mellitus, cirrhosis, biliary tract disorders and 
alcoholism among patients, which may have influenced the mortality rate. 
Secondly, we wanted to investigate the acquisition of EPE and CPE among 
healthy people those were travelling to high prevalence of EPE and CPE region. 
We included 188 healthy adult Swedish tourists with planned travel to high EPE 
and CPE prevalent regions; Southeast Asia, Indian subcontinent, North Africa and 
the Middle East. We excluded 13 travellers from the analysis who were colonized 
with EPE before travelling. We found 67 out of 175 healthy Swedish tourists were 
colonized with different EPE strains; E. coli (n=65), K. pneumoniae (n=1) and 
Citrobacter freundii (n=1). We also observed that healthy Swedish tourist were not 
colonized with any carbapenemase producers. The most prevalent EPE type was 
CTX-M type detected in 61 isolates; 49 isolates were CTX-M-1 and 12 isolates were 
CTX-M-9. We also observed that Swedish healthy tourists were colonized with 
low virulence EPE isolates. Only six isolates acquired pyelonephritis-associated 
 pili-encoding genes (pap) genes and travellers were colonized with these six 
isolates from India. Recently emerging colistin resistance gene mcr-1 harboring 
E. coli was colonized with a traveler travelling to Thailand. We observed that only 
8 out of 65 isolates were belonged to MDR associated phylogroups B2 and all of 
these 8 isolates were isolated from the travellers had travelled to South-East Asia 
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(n=2) and Indian subcontinent (n=6). As expected, highest colonization rates was 
observed in Indian subcontinent (49%) and northern Africa (44%) whereas lower 
rates was observed in Southeast Asia (19%) and Turkey (10%). We also observed 
that  diarrhea and antibiotic treatment during the trip were associated with EPE 
colonization, but chronic diseases were negatively associated with EPE coloni-
zation. We did not find any significant association between sex, age, duration of 
trip, intake of proton-pump inhibitors, or use of oral cholera vaccine with EPE 
colonization. 
Thirdly, we wanted to evaluate a rapid detection and characterization methods 
for CPE and EPE due to the urgent need of rapid, simple and reliable phenotypic 
detection method for low income settings. In low income settings, prevalence of 
EPE and CPE is high and can be migrated to low prevalence EPE and CPE area like 
Nordic countries (Showed in travellers study). We evaluated a commercial version 
of RAPIDEC® CARBA NP, colorimetric liquid-based assay for rapid detection of 
carbapenemases. The in-house Carba NP assay can be setup but will be challenging 
for routine laboratories due to high instability of carbapenems. To our knowledge, 
we reported for the first time two-centre evaluation of RAPIDEC® CARBA NP 
assay against 276 Gram-negative bacilli. We observed that RAPIDEC® CARBA 
NP assay can detect carbapenemases in less than 2.5 hours with high sensitivity 
(97.8%) and specificity (98.5%) without requiring any specialized equipment. 
Finally, we evaluated a novel method based on optical DNA mapping assisted 
with CRISPR/Cas9 to characterize plasmids during EPE outbreak. This method 
should be equally useful to trace CPE outbreak, although this was not investigated 
in this paper. The basic of this method is, CTX-M group 1 gene was targeted by 
guide RNA to guide Cas9 to cut the same location of 80 kbp plasmid of all iso-
lates. Using barcodes, location of CTX-M-1 gene (targeted gene) can be seen. We 
reported that this method successfully can detect different size of plasmids; small 
size 80 kbp and larger plasmid (162-222) kbp. We also reported that this method 
can track the changes of plasmid over time. We reported deletions in three plas-
mids of three isolates with different size (~5 kbp), (~55 kbp) and (~31 kbp) and 
inversion of 31 kbp in another isolate.
Despite not being part of the aims of the thesis, it is worth mentioning that rapid 
antimicrobial susceptibility testing (AST) is urgently needed. Although, it was not 
the goal of this thesis but to facilitate treatment decision and to prevent spread-
ing of antimicrobial/antibiotic resistance resulting from abuse (misuse/overuse) 
of antibiotics, there is a major demand for development of rapid AST. AST used 
in this thesis (currently available techniques) require 16-18 hours to read out the 
results, but with novel methods this could drop to 30 minutes. This will be dis-
cussed in detail in the future perspectives section of this thesis. 
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5.2 Phylogroups of K. pneumoniae
Over the years, phylogenetic analysis of K. pneumoniae has resulted in the  division 
into several phylogroups. Phylogroups KpI to KpIV were first reported in the year 
2001 (175). Then, two more phylogroups KpV and KpVI were reported in 2017 
(188).  Another phylogroup KpVII has been reported recently (189). Phylogroups 
KpI to KpIV and KpVI have taxonomic status. Phylogroups KpI to KpIV and 
KpVI represent different taxa K. pneumoniae (sensu stricto), K. quasipneumoniae 
subsp. quasipneumoniae, K. variicola and K. quasipneumoniae subsp. simili-
pneumoniae respectively. Phylogroups KpV and KpVII have no taxonomic status 
but Brisse and colleagues have recently proposed the names K. variicola subsp. 
tropicalensis for KpV and K. africanensis for KpVII (189). In this thesis, we tested 
three phylogroups; KpI, KpII and KpIII in project I. Phylogroups KpIV-KpVII were 
not tested. In fact, KpV and KpVII were not reported during the time we studied 
project I. We were able to identify all three phylogroups known at the time; KpI 
(69%), KpII (6%) and KpIII (24%). To our knowledge, this study was the first to 
find association between phylogroups, virulence factors and mortality data in a 
well-defined geographical area. In the year 2004, a study based on (n=420) isolates 
from 26 European hospitals also reported three phylogroups; KpI (82.1%), KpII 
(6.9%) and KpIII (11%) (190). 
5.3 Misidentification of K. variicola and 
K. quasipneumoniae
The conventional clinical microbiology laboratory techniques are unable to distinguish 
K. pneumoniae (KpI), K. variicola (KpIII) and K. quasipneumoniae (KpII) due to their 
closely overlapping biochemical properties (191). K. pneumoniae is adonitol positive 
but K. variicola and K. quasipneumoniae are adonitol negative. Adonitol fermentation 
and indole positivity are considered as the classifier but the phenotype is unstable and 
not consistent among all the isolates of these three species (192). The correct bacterial 
species identification using molecular diagnostics mainly depend on the availability 
of the databases. The database of common molecular diagnostics platforms; Verigene, 
Vitek or MALDI-TOF MS did not include K. variicola and K. quasipneumoniae until 
recently so either they were not identified or misidentified (193). Previously it has 
been reported that 2.5% to 10% of K. pneumoniae were misidentified and should have 
been reported as K. variicola (194-197). The current Bruker MALDI-TOF MS micro-
organism database included K. variicola in the year 2015 but still K. quasipneumoniae 
was not included, causing continuation of misidentifications (193, 194). Previous 
studies have showed overrepresentation of phylogroup KpI (K. pneumoniae) but in 
this study phylogroup KpIII (K. variicola) was also relatively common (190, 198). 
Previously, it has been reported that K. variicola causing bloodstream infection was 
incorrectly identified as K. pneumoniae using classical and automated identifications 
but later, correctly identified as K. variicola using next-generation sequencing (199).
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5.4 Association of phylogroups, bacterial factors, 
mortality and comorbidity
In the first project of this thesis, to our knowledge we are the first to discuss the 
possible association with phylogroups, bacterial factors (virulence factors, sero-
types), mortality and comorbidity. In accordance with previous studies we observed 
17.3% overall 30-day mortality on BSI caused by K. pneumoniae (200, 201). 
High mortality ranges of 20% to 62% has been observed in Klebsiella bacteremia, 
reported previously (202). A recent study showed that the 30-day mortality rate was 
40.7% in classical K. pneumoniae bacteremia compared with 37.1% hyperviru-
lent K. pneumoniae bacteremia (203). One explanation could be that less virulent 
strains were acquired by severe sick patients and patients died due to underlying 
diseases. In our study, we also observed that a total of 10 isolates of K. variicola 
(Phylogroup KpIII), 13 isolates of K. pneumoniae (Phylogroup KpI) and one iso-
late of K. quasipneumoniae (Phylogroup KpII) were linked with 30-day mortality. 
Among them, only 3 isolates out of 24 cases of 30-day  mortality were associated 
with investigated virulence factors; K54 (n=1), mucoid phenotype (n=1) and/or 
virulence genes (wcaG n=1 and wcaG/allS n=1). According to our knowledge, 
we reported for the first time that K. variicola bacteremia in adults were associ-
ated with higher 30-day mortality than bacteremia caused by K. pneumoniae. A 
recent study based on an outbreak of multidrug-resistant (MDR) K. variicola in 
a neonatal unit of Dhaka Medical College at Dhaka, Bangladesh in the year 2016 
to 2017 reported that K. variicola is also highly associated with mortality (54.5%) 
due to BSI in neonates (204). In our study we observed a significant (P=0.037) dif-
ference in mortality among KpI and KpIII that has been shown both in univariate 
analysis and in multivariate analysis after adjustment of age, gender, time to get 
antibiotic treatment, comorbidity and polymicrobial infections. Clinical condi-
tions of patients were more or less similar so that the reason for the difference in 
mortality between phylogroups remains inexplicable. In this type of study, it was 
complicated to measure time to appropriate antibiotic treatment and other recom-
mended therapy due to the severity of disease. In this study, we also observed very 
low degree of antibiotic resistance but did not observe any significant changes 
among survivors and deaths, although 55.4% of the patients received adequate 
antibiotic treatment within 4 hours and 87.1% patients received adequate anti biotic 
treatment within 24 hours. Here, we studied BSI and mortality, but BSI may in 
many cases not be the main cause of death. Previously published reports sug-
gested that several comorbidities such as malignancy, diabetes mellitus, cirrhosis, 
biliary tract disorders and alcoholism may suppress patient immune system and 
contributed to develop K. pneumoniae infections which may influence mortality 
rate (203, 205-207). We also found in our study that K. pneumoniae (phylogroup 
KpI) isolates were more resistant than K. variicola (phylogroup KpIII) isolates, 
which is in accordance to previously published report (190, 198). In our study we 
found only five isolates that were considered multidrug-resistant (MDR) belong-
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ing to phylogroup KpI and all were ESBL-producers. This is in accordance with 
previously published report, they also found that most of the ESBL-producing 
isolates belonged to phylogroup KpI (208). 
5.5 Phylogroups of E. coli
Six phylogroups; A, B1, B2, C, D and E of E. coli were first defined by a study 
based on multi-locus enzyme electrophoresis on 35 enzyme loci (209). Later, pres-
ence of all these above mentioned phylogroups were confirmed by DNA methods; 
rDNA restriction fragment length polymorphism, random amplified polymorphic 
DNA, MLST, whole genome sequencing (WGS)(210-212). Another new phylo-
group F has been reported recently as a seventh phylogroup of E. coli (213). The 
most ancient phylogroups of E. coli are B2 and D, then emerged E, followed by the 
most recently diverged phylogroups C, B1 and A (213). The phylogenetic history 
of this species and the lifestyle of the strains are associated. The majority of extra-
intestinal pathogenic strains belonged to phylogroups B2 and D whereas strains 
of recently diverged phylogroups C, B1 and A are associated with diarrhoeagenic 
strains (30). The latest phylogroup G has been reported in 2019 consisting of 
isolates being an intermediate between the phylogroup F and B2. Isolates of this 
phylogroup have been found to be associated with extra-intestinal virulence and 
acquired MDR (30). In this thesis we did not test all eight phylogroups of E. coli, 
since several were reported after the study was completed. We observed in this 
thesis that phylogroup A (43.1%) was more predominant than phylogroup B2 
(12.3%) which is in accordance with the recently published report (2018), where 
they also found domination of phylogroup A (73%) than phylogroup B2 (33%) in 
travellers (214). Our findings and this recent study suggested that colonization of 
MDR strains were very few in healthy Swedish tourists. Strains of phylogroup A 
are responsible for causing dysentery, and we found that 28.7% of travellers suf-
fered from travellers’ diarrhoea. Based on the virulence profile of E. coli in this 
thesis we suggest that a majority of healthy travellers are colonized by less virulent 
strains of E. coli. In a previous study from our research group, we found B2 was 
the predominant phylogroup in stool samples which is in contrast of this study 
(215). It could be an explanation that previous study was performed on patients 
whereas the current study was performed on healthy populations. 
5.6 Colonization and duration of EPE and CPE 
in travellers
To our knowledge, acquisition of CPE colonization is still rare in healthy travel-
lers. In our study, we did not observe any CPE colonization in healthy tourists, 
but we observed that 34.9% of healthy tourists were colonized with CTX-M type 
EPE. The risk of developing clinical infections by EPE colonizing strains is not 
yet defined. It has been reported previously that 7.4% individual prior colonized 
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with third generation cephalosporin-resistant Enterobacteriaceae were at risk of 
acquiring bacteremia (216). In our study all isolates were likely less prone to cause 
clinical infections, as the majority of the isolates had limited number of virulence 
determinants and were community-acquired. During 26 months of follow-up of 
EPE positive travellers we did not observe any clinical infections due to EPE. It 
suggests that there is a risk of being colonized with EPE while travelling to high EPE 
regions, but the risk is very low for future clinical infections due to EPE coloniza-
tion. However, there is still potential risk of dissemination of resistant strains from 
healthy travellers to patients, who may have a greater risk of developing disease. 
A recently published report mentioned that 113 days and 60 days were the mean 
and median duration of carriage of CTX-M-EC, respectively. They found 31% 
of travellers being CTX-M-EC carrier at 6 months after travel. The longest dura-
tion of carriage of CTX-M-EC they observed was 11 months after travel (214). 
Another recent study reported that 11.3% travellers were persistently colonized 
at 12 months after travel (217) The limitation of our study was that we did not 
perform long term follow-up ESBL-EC carriage. 
5.7 Rapid detection of CPE 
In this thesis, we have evaluated a commercial version of RAPIDEC® CARBA 
NP test to detect carbapenemases and we found that this test was highly sensi-
tive (97.8%) and specific (98.5%). We detected class A, including weak class A 
carbapenemase GES-5 and IMI, and class B carbapenemases using commercial 
version of RAPIDEC® CARBA NP assay. We observed that this commercial 
 version was unable to detect two A. baumannii producing OXA-23 and OXA-24 
and one K. pneumoniae producing OXA-48 but these enzymes were detected in 
other strains by RAPIDEC® CARBA NP thereby this issue was not consistent 
with this assay. A previous study also reported the failure of detection of some 
OXA-48 isolates with in-house CARBA NP test (218). The overall sensitivity 
92.2% and specificity 100% were reported by a single-centre study (219). They 
also reported increased sensitivity to 100% by doubling the inoculum of bacteria 
but we did not follow this approach as in principle specificity could be affected 
negatively by this approach. However, the developer of original Carba NP test, 
Poirel and Nordmann also evaluated commercial version of RAPIDEC® CARBA 
NP assay against 176 isolates and reported 5 out 98 carbapenemase producers 
were detected as false negative; P. aeruginosa producing GES-2, A. baumannii 
producing OXA-23, Acinetobacter pittii producing OXA-40, and Proteus mirabilis 
producing chromosomally encoded OXA-23 (125). They also reported 3 out of 75 
non-carbapenemase producers as false positive; two A. baumannii producing chro-
mosomal AmpCs and one Proteus vulgaris producing CMY-2. We also observed 
two false positive results; one Enterobacter cloacae with impermeability and one 
P. aeruginosa with OprD loss in our study.  Any other phenotypic carbapenemase 
detection methods were not tested in this thesis. 
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5.8 Plasmid characterization using CRISPR/Cas9 
assisted optical DNA mapping
In this thesis, a novel method based on optical DNA mapping combined with 
CRISPR/Cas9 was developed for rapid and detailed characterization of plasmids 
from bacterial isolates. The purpose of this study was to characterize the ESBL 
plasmids from an NICU outbreak at Karolinska University Hospital Stockholm, 
Sweden and investigate whether several different ESBL-producing bacterial spe-
cies were present due to horizontal spread of plasmid. 
Using Cas9, we were able to identify the exact location blaCTX-M-1 gene on one 
particular plasmid. Analyzing barcode from optical DNA mapping we were able 
to confirm the presence of particular plasmid in other isolates during outbreak (if 
any). We observed, at the beginning of outbreak blaCTX-M-1 gene producing plasmid 
was identical in all isolates and it persisted within neonates more than a year after 
discharge from the NICU. DNA mapping also revealed that outbreak ESBL-KP 
plasmid was different from the ones observed in ESBL-EC and in one strain of 
ESBL-KP. This suggests that no horizontal transfer had occurred between these 
species. We also observed a small second chain of transmission in three patients as 
we found the same ESBL-EC plasmid in isolates from three patients. The blaCTX-
M-1 gene was located on the chromosome in these strains. We could conclude that 
additional plasmid-mediated dissemination of resistance was not taking place in this 
outbreak. The comparison between long-read PacBio sequencing and theoretical 
barcodes suggest that the prediction of the location of the blaCTX-M-15 gene by Cas9 
restriction was correct.
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6 CONCLUSIONS
Paper I
1. Population structure of K. pneumoniae revealed three well-defined phylogroups; 
K. pneumoniae (KpI), K. quasipneumoniae (KpII) and K. variicola (KpIII). 
Phylogroup KpIII isolates were highly associated with 30-day mortality. High level 
of comorbidity was observed among the isolates of phylogroup KpI and KpIII. 
2. Highly virulent K. pneumoniae clones are still rare in Stockholm area. Isolates 
belonging to phylogroup KpIII were more often associated with mortality than 
phylogroup KpI and KpII but were not associated with known virulence factors.
Paper II
3. The RAPIDEC® CARBA NP assay can detect carbapenemases within less than 
2.5 hours with high sensitivity and specificity without requiring any specific 
equipment. 
4. RAPIDEC® CARBA NP assay is a rapid, simple, and reliable tool for detection 
of carbapenemases.
Paper III 
5. Isolates belonging to phylogroup B2 were only found in Southeast Asia and 
Indian-subcontinent but were absent in North Africa and Middle East.
6. Carbapenemases were absent, but we found the mcr-1 gene encoding colistin 
resistance in an ESBL-producing strain from one of the travellers.
7. Antibiotic treatment during travel can increase the risk of EPE colonization.
8. The risk of colonization of EPE is higher than the risk of colonization of CPE 
while traveling to high-prevalence areas.
Paper IV
9. Optical DNA mapping combined with CRISPR/Cas9 method can readily 
 demonstrate the number of plasmids, their size, and the location of resistance 
genes of interest
10. During an outbreak the plasmids change to a limited degree (e.g. deletions and 
inversions), and the plasmid typing can serve as an indirect tool for detecting 
strain outbreaks.
11. The findings with optical mapping were confirmed with long-read sequencing 
(PacBio), confirming the reliability of the novel technique
12. Optical DNA mapping could be a clinically useful novel molecular tool 
to characterize plasmids during hospital outbreaks with ESBL-producing 
Enterobacteriaceae.
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7 FUTURE PERSPECTIVES
Antibiotic resistance is a severe threat to public health. It has been estimated that 
10 million deaths and more than one trillion dollars in total economic impact 
would be the cause of antimicrobial resistance by 2050 if no action is taken. It is 
important for health care settings to determine antimicrobial susceptibility rapidly 
to be able to facilitate treatment decisions and avoid unnecessary broad-spectrum 
therapy. No phenotypic AST method has so far been available to obtain results 
within 30 minutes directly from clinical samples. An overnight culture is required 
to perform AST using currently available methods and all AST used in this thesis 
were performed following currently available methods. Depending on time and 
sample type (pure isolates/ direct samples) the following methods could be used 
in the near future to develop rapid phenotypic antibiotic susceptibility testing 
methods for clinical laboratories. 
Atomic force microscopy (AFM) cantilever: The bacteria can accumulate on the 
surface of the cantilever. The movement of the bacteria can increase the amplitude 
of the cantilever fluctuations. These fluctuations can be sensed by using a sensing 
chamber. If bacteria are susceptible to antibiotics they will demonstrate decreased 
movement. Thus, the fluctuation of the cantilever will decrease and vise-versa. 
This can be used to identify MIC. It has been reported previously that MIC can 
be determined within 15 minutes after antibiotics treatment (220). Pure culture 
isolates may be required to perform the test, for which reason it may have to be 
combined with traditional culture before AST can be done from colonies. 
Microfluidic agarose channel (MAC) system: In this method, AST can be deter-
mined by using immobilized bacteria in the agarose media. The mixture of bacteria 
and liquid agarose gel will be injected into the microfluidic channel and bacteria 
will be immobilized within the channel. Bacterial growth media and antibiotics will 
be introduced into the agarose by using a capillary valve. Antibiotic will diffuse 
into the agarose matrix that can be monitored in real time by using microscopy. 
Using the single bacterial time lapse images, growth of bacteria can be determined 
in different concentrations of antibiotics (221).  This method may also require pure 
bacterial colonies and could be challenging to use directly on samples.
Isothermal micro calorimetry (IMC): In this method, bacterial growth can be 
determined by measuring the heat flowrate of a given bacterial suspension. In prin-
ciple, produced heat is proportional to the reaction rate in the suspension. Using 
this data, MIC can be determined (222). This method can also distinguish between 
bacteriostatic and bactericidal effect of antibiotics. Using this method, antibiotic 
can be grouped into different mode of action; cell wall synthesis inhibitors, DNA/
protein synthesis inhibitors. This method can also be used for classification of new 
antibiotics. This method normally takes ~24 hours to obtain MIC results. Thus far, 
it has only been used on cultivated bacterial colonies.
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Digital loop-mediated isothermal amplification (dLAMP): A recent published 
article reported that they have developed this ultrafast method for performing AST 
within 30 minutes from clinical urine samples, published 2017. It has been men-
tioned in this report that AST can be determined using digital nucleic acid quan-
tification to measure the phenotypic response after antibiotic treatment to E. coli 
containing urine samples. In this report it has also been described that they used 
digital quantification of a DNA marker to lower the antibiotic exposure time to 15 
minutes. Then, they showed digital AST (dAST) can distinguish the response of 
target pathogen and commensals. Finally, a rapid, high-resolution measurement 
method for quantifying NA targets was developed and optimized to reduce the 
measurement step to less than 10 minutes (222, 223).  This method, like many 
other methods may work best on single colonies, and it is not clear whether it 
would work directly on complex samples.
Finally, advancement of development of rapid AST methods will provide health 
care providers with a powerful tool to tailor antimicrobial treatment, and thus to 
fight antimicrobial resistance. 
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